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Preface  
 
Picornaviridae are among the most diverse and oldest known viral families that include many 
important pathogens of humans and animals. They are small, icosahedral (+)ssRNA viruses, 
causing a variety of diseases, such as encephalitis, and poliomyelitis. Vaccines are available for 
poliovirus, hepatitis A virus and foot and mouth disease virus, but no effective prophylaxis is 
implemented for other picornaviruses. Thus far, anti-viral research has focused on the capsid, 
whereas inhibitors targeting non-structural proteins (i.e. proteases, helicases, polymerases) have 
remained largely unaddressed.  
The project was focused on structural and biochemical characterization of the enterovirus-B93 
(EV-B93) 3C protease alone and in complex with several covalent inhibitors. The second 
objective was to identify the first non-covalent potent inhibitors of the EV-B93 3C protease 
and their further biochemical, antiviral, and structural evaluation. 
 
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List  of abbreviations and symbols 
 
#   number 
°C    degree Celsius 
ΔG    Gibbs energy 
[v/v]    volume per volume 
[w/v]    weight per volume 
1,8-ANS   1-anilinonaphthalene- 8-sulfonic acid 
2,6-TNS   2-p-toluidinyl-6-naphthalene sulfonate 
3D    three dimensions 
3CL protease   3C-like protease 
5’UTR   5’ untranslated region 
Å    Angstrom 
ADMET   absorption, distribution, metabolism, secretion, toxicity 
Ac    acetyl 
AiV    aichi virus 
APS    ammonium persulfate 
ATP    adenosine-5’-triphosphate 
C-terminal   carboxy-terminal 
Cbz   carboxybenzyl 
CDK2    cyclin-dependent kinase 2 
clogP    calculated logP 
CoV    coronavirus 
CPE    cytopathic effect 
CV    column volume, coxsackievirus 
Da    Dalton 
DMAB   dimethylaminoborane 
DMSO   dimethylsulphoxide 
DNA    deoxyribonucleic acid 
DSS    4,4-dimethyl-4-silapentane-1-sulfonic acid 
DTT    dithiothreitol 
EC50    half maximal effective concentration 
EDC    1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
ERAV    equine rhinitis A virus 
ERBV    equine rhinitis B virus 
EV    enterovirus  
FABP4   fatty acid binding protein 4 
FBDD   fragment-based drug design 
FDA    Food and Drug Administration 
FMDV   Foot-and-mouth disease 
g    gram 
GAL4BD   GAL4 binding domain 
h    hour 

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HAV   hepatitis A virus 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His-tag   poly(6) histidine-tag 
HPLC    high performance/pressure liquid chromatography 
HRV    human rhinovirus 
HSQC   heteronuclear single quantum correlation 
HTS    high-throughput screening 
Hz    hertz 
IC50    half maximal inhibitory concentration 
IMAC    immobilized metal ion affinity chromatography 
IRES    internal ribosomal entry 
k    kilo (103) 
Kd    dissociation constant 
Ki    inhibitory constant 
koff    dissociation rate constant 
l    liter 
LB    Luria-Bertani 
LE    ligand efficiency 
μ    micro (10-6) 
M    molar, marker 
m    mili (10-3) 
m/z    mass-to-charge ratio 
MALDI-TOF   matrix-assisted laser desorption/ionization time-of-flight 
MD    molecular dynamics 
min    minute 
MPD    2-methyl-2,4-pentanediol 
MS    mass spectrometry 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW    molecular weight 
MWCO   molecular weight cut-off 
n    nano (10-9) 
N-terminal   amino-terminal 
Ni-NTA   nickel-nitrilotriacetic acid 
NHS    N-hydroxysuccinimide 
NMR    nuclear magnetic resonance 
NROT   number of rotational bonds 
P    partition coefficient between octanol and water 
PAGE    polyacrylamide gel 
PDB    protein data bank 
PCR    polymerase chain reaction 
PEG    polyethylene glycol 
ppm   parts per million 
PSA    polar surface area 
PSV    porcine sapelovirus 

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PV    poliovirus  
RA    relative activity 
RLU    relative light unit 
RMSD   root mean square deviation 
RNA    ribonucleic acid 
RPC    reverse phase chromatography 
rpm    revolutions per minute 
RU    response unit 
RV    rhinovirus 
s    second 
S/N    signal-to-noise ratio 
SAR    structure-activity relationship 
SARS    severe acute respiratory syndrome 
SDS    sodium dodecyl sulfate 
SPR    surface plasmon resonance 
(+)ssRNA  positive single-stranded RNA 
STD    saturation transfer difference 
TEMED   N,N,N,N-tetramethylendiamine 
TFA    trifluoroacetic acid 
TINS    target immobilized NMR screening 
Tm    melting temperature 
Tris    Tris(hydroxymethyl)aminomethane 
TSA    thermal shift assay 
V    Volt  
VP16AD   VP16 activation domain 
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Amino acids abbreviations 

1-letter code 3-letter code amino acid 
A Ala alanine 
R Arg arginine 
N Asn asparagine 
D Asp aspartic acid 
C Cys cysteine 
E Glu glutamic acid 
Q Gln glutamine 
G Gly glycine 
H His histidine 
I Ile isoleucine 
L Leu leucine 
K Lys lysine 
M Met methionine 
F Phe phenylalanine 
P Pro proline 
S Ser serine 
T Thr threonine 
W Try tryptophan 
Y Tyr tyrosine 
V Val valine 
  
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1.1 Drug discovery 
 
Drug discovery is the fascinating process through which potential new medicines are found. In 
the past, active ingredients were identified from traditional remedies or by unanticipated 
discovery. Later intact cells or whole organisms were treated by series of synthetic compounds, 
natural products or extracts in order to select substances with desirable therapeutic properties. 
The sequencing of the human genome enabled rapid cloning, expression and purification of a 
large number of proteins. Since then, high-throughput screening of large quantities of 
molecules against isolated biological targets has become a common practice. The selected hits 
from the screens are subsequently tested in cellular and animal models for efficacy. Most 
frequently, optimization of the most promising compounds is needed to improve their affinity, 
selectivity (reduction of possible side effects), potency, metabolic stability (increase of half-life), 
and oral bioavailability. Once a compound fulfills the requirements established for a drug 
candidate, it will undergo the process of drug development prior to clinical trials [1]. 
 
1.1.1 Fragment-based drug discovery vs.  high-throughput screening: a matter 
of chemical space 

Drug discovery methods are divided into several techniques described below (Figure 1.1). 
Fragment-based drug discovery (FBDD) emerged as a novel strategy for hit identification in 
the past decade. The power of the FBDD-concept was first described by Fesik, Hajduk and 
colleagues in the late 1990s [2], [3]. Since then, the field has vastly expanded, and the 
fragment-based approach has started playing an important role in the discovery of drugs, many 
of which have now entered the clinic. Nowadays, this method is widely applied by scientists 
working in both academia and the industry [4]. 
The FBDD approach is recognized as a highly efficient tool for drug discovery, and offers an 
alternative to more traditional methods such as high-throughput screening (HTS). Despite the 
fact that HTS has taken hold in most pharmaceutical companies, and allows significantly 
a larger number of compounds to be screened against a target of interest, thus far the industry 
has not succeeded in generating the desired level of productivity. Undoubtedly, HTS has 
produced high quality lead molecules for many drug discovery programs, however, the hit rates 
are generally low, particularly when screening against challenging targets [5], [6]. In the case of 
fragment screening, the fragments exhibit lower affinities than HTS hits, but simultaneously 
show higher ligand efficiencies [7], thus proving that with these small molecules a larger 
proportion of the fragment is truly involved in the binding. In other words, smaller, less 
 

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complex molecules have fewer possibilities to bind to the target, hence this leads to a more 
effective probing of the available chemical space.  
Additionally, the optimization of lead compounds in HTS can be problematic owing to the 
often large and relatively lipophilic nature of the screening hits [8]. In contrast, the 
identification of a starting compound is guaranteed in the application of fragment screening 
that identifies smaller soluble ligands even in the most difficult places, such us protein-protein 
interaction regions. According to a theoretical model proposed by the Novartis Group, the 
observed hit rates in low molecular weight screenings were 10- to 1,000-fold higher than in 
conventional HTS assays [9]. Despite the fact that the size of a fragment library is typically 
smaller (500-10,000 compounds) than an HTS library (up to 106 molecules), it is easier to 
obtain a more structurally diverse collection of low molecular weight compounds that can 
cover the chemical ligand space more effectively. Therefore, the hit identification for most 
targets is often faster and allows an effective subsequent hit-to-lead elaboration (Figure 1.1).  

 
 
 
 
 
 
 
 
 
 
Figure 1.1 Comparison of high-throughput screening (HTS, top) with fragment-based screening 
(linking and growing strategy, middle and bottom). Adapted from [10]. 
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1.1.2 What is a fragment? 

Fragments used in FBDD are defined as low molecular weight (MW <300 Da), moderately 
lipophilic (calculated logP ≤3, where P is the partition coefficient between octanol and water), 
highly soluble organic molecules, which typically bind to their target with low affinity (in the 
μM to mM range). Also, the number of hydrogen-bound donors and acceptors should be ≤3. 
Some data suggested the amount of rotational bonds (NROT) ≤3 and polar surface area (PSA) 
should not exceed 60 Å2. These general principles, known as “the rule of three” [11], could be 
helpful in designing fragment libraries for an efficient discovery of hits. Subsequently, they can 
be further optimized into drug-like molecules with good physicochemical properties compliant 
with Lipinski’s “rule of five” [12].  
 
1.1.3 The drug-like molecule 

Lipinski suggested the following guiding criteria for orally available small-molecule drugs: MW 
<500 Da, calculated logP <5, number of hydrogen bonds ≤5, number of donors and acceptors 
≤10. This concept of drug-likeness is not always obeyed by natural products or natural-product 
like molecules (e.g. cyclosporine). Nevertheless, they may be easily absorbed after oral 
administration. The Lipinski’s rules were enhanced by Clark and Picket who discovered that 
the polar surface area (PSA) is another important property for a compound to exhibit high oral 
bioavailability [13]. Consequently, more polar, less lipophilic compounds with a PSA of 110–
140 Å2 can be absorbed more efficiently and display low toxicity [14]. Another observation was 
described by Veber and colleagues who noticed that the maximum number of rotatable bonds 
for optimal oral bioavailability is seven [15]. A potential drug candidate should not only fulfill 
the Lipinsky’s “rule of five”, but also possess appropriate ADMET properties (absorption, 
distribution, metabolism, secretion and toxicity). These parameters are exceptionally difficult 
to optimize in the case of large (ca. 500 Da) and often lipophilic compounds selected by HTS 
approach. About 50% of drugs in general fail in clinical trials due to inadequate ADMET 
attributes [16], [17], [18], [19], [20]. 
 
 
 
 
 
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1.1.4 Hit selection and lead optimization 

The concept of ligand efficiency (LE) introduced by Hopkins and colleagues [7] can be used 
for quality evaluation of the preliminary screening hits and further assessment of lead 
optimization. The ligand efficiency index (LE) is defined as:  
 


 
where   is the free binding energy (Gibbs energy) of the ligand for the protein of 
interest while  is the number of heavy (non-hydrogen) atoms in the 
ligand. Free binding energy is defined by:  
   
where  is the gas constant, - the absolute temperature and  the dissociation constant. It is 
possible to describe LE more practically using parameters that can be measured directly: 
 


 
 
The parameters: , p,  as well as   can define potency equally well. LE is 
a useful method to measure the impact of addition of more atoms to a molecule on its potency. 
Molecules that reach a desired potency but possess fewer heavy atoms are defined as more 
efficient. In successful optimization, potency increases linearly with molecular weight. For this 
reason, it is crucial to select the initial hit with the most optimal efficiency for further lead 
elaboration.  
Figure 1.2 shows the general relationship of the potencies/efficacies and the molecular weight 
of selected HTS hits and fragments [21]. Fragment hits are usually in the range between 120-
250 Da and of low potency (mM to 30 μM). The potency of selected fragment needs to be 
increased in order to acquire a useful lead, nearly always resulting in a higher molecular weight. 
Hits coming from the HTS approach have a wider range of molecular weight (250-600 Da), 
and tend to be of higher potency (high nM range to low μM). These molecules have to be 
optimized in order to obtain a good quality lead of the same or higher potency and a reduced 
molecular weight. Years of experience show this is a challenging goal to achieve. 
 
 
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Figure 1.2 General relationship of potencies/efficacies and molecular weight of selected HTS hits and 
fragments as starting points for lead identification and drug discovery. 
 
1.1.5 Detection of fragment binding 

One of the major challenges of fragment-based drug discovery is an effective and reliable 
detection of low-affinity binders. Since fragments possess millimolar or high micromolar 
affinity to the target of interest, they need to be screened at a higher concentration using a very 
sensitive method. Typically, most biochemical and binding assays fail at this stage; however 
they are the simplest and cheapest approaches available. Performing a biochemical assay 
requires the use of highly concentrated compounds, typically 250-1,000 mM, and may cause 
various problems including target denaturation, toxicity to cells, false positives (due to 
compound aggregation) and false negatives (due to lack of solubility). For all these reasons, 
a variety of alternative biophysical methods have been developed to improve the selection of 
fragment hits. 
 
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1.1.5.1 Nuclear Magnetic Resonance 

The first published description of Fragment-Based Lead Discovery (FBLD) was the Structure-
Activity Relationship (SAR) by Nuclear Magnetic Resonance (NMR) method by the Abbott 
Group. They detected binding of ligands to specific regions by the perturbation of HSQC 
(Heteronuclear Single Quantum Correlation) spectrum of an isotopically-labeled protein [2, 
22]. This technique relies on the changes in chemical shifts of specific protein residues in the 
absence and presence of small compounds. However, it requires large quantities of the protein 
(exceeding 200 mg), and is limited to relatively small proteins (less than 30-40 kDa) [2].  
Another NMR-based method for fragment screening is the so-called ligand-detected approach, 
in which changes in the NMR properties of the fragments are monitored, rather than 
properties of the protein itself. There are several techniques in use [23]. The most common is 
saturation transfer difference (STD) [24], which is based on the differences in relaxation 
between small compounds and the target protein. This method uses smaller amounts of 
protein, require no isotope-labeling, and has no upper size limit for the protein target. 
Moreover, STD NMR is an excellent approach for determining the binding epitope of 
a ligand-the piece of information vital for directed drug development. 
 
1.1.5.2 Surface plasmon resonance 

Surface plasmon resonance (SPR) is another ligand-screening technique that has gained 
importance in recent years. This label-free study of interactions between molecules has been 
known for over 20 years [25]. Typically, a protein is immobilized on a chip, and varying 
concentrations of ligands are allowed to flow over it. Molecules that bind to the protein cause 
changes in the reflective properties that depend on the ratio of the ligand mass to the protein 
mass. In some cases, association and dissociation rates can be directly determined, however, in 
the case of fragments these are usually too rapid to be measured. Although SPR has been 
available for some time, the recent improvement in sensitivity and increased experience in 
robust attachment of a target to the chip surface have led to an extended use of this technique. 
It is important to note that although SPR experiments do not require extensive training, it is 
very easy to set up the method incorrectly or to be misled by the artifacts. When done 
properly, SPR can be a very useful tool, not only for obtaining dissociation constants, but also 
for stoichiometry estimation [26-28].  
 
 
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1.1.5.3 X-ray crystallography 

Crystallography and protein-detected NMR are unique methods that provide detailed 
information on how (including low-affinity) fragments bind to protein targets. X-ray 
crystallography has the advantage over NMR of yielding high-resolution structural data, and it 
can be employed for large proteins. Nowadays, most companies use crystallography as a 
primary screening technique in FBDD campaigns. However, it may also be applied for 
characterization or confirmation of the binding mode of previously selected hits, thus 
providing valuable insight into SAR of the fragments and potential areas for a future 
development [10, 29-32]. It is worth remembering X-ray crystallography has also numerous 
limitations. Generation of a suitable protein in high yield requires an effective expression and 
purification of the target protein. This process is time-consuming and labor-demanding. 
Reproducible production of well-diffracting crystals and its optimization is another important 
step. There are two options to obtain co-crystal structures with compounds of interest: soaking 
the fragment hits into already-existing crystals and co-crystallization. The collected data result 
in a 3D model that may be useful although also misleading. In the case of low resolution 
structures, it is possible to misassign the position and conformation of a ligand. Frequently, the 
potential hits are not noticed (false negatives) due to occlusion of the binding sites by crystal 
contacts, or due to ligand binding requiring a conformational change of the protein that is not 
possible within the crystalline state. Finally, a crystal structure provides no or limited 
information on the binding affinity of the ligand, and requires the use of additional methods to 
confirm its presumed functional activity.  
 
1.1.5.4 Fluorescence melting assay 

The thermal shift (Thermofluor) method is another biophysical technique widely used as 
a primary screening. It is based on monitoring the changes in temperature at which the protein 
of interest unfolds in the presence of a putative ligand. This is possible when Sypro Orange, 
a dye that preferentially binds to unfolded hydrophobic parts of a denatured protein increasing 
its fluorescence, is added to the protein-ligand mixture. Through measuring the fluorescence 
emission over a range of temperatures, it is possible to determine the melting temperature 
(Tm) of a protein. Ligands usually stabilize their hosts against thermal denaturation, so 
a molecule that increases a protein’s melting temperature is considered a hit [33]. In spite of 
being fast and inexpensive, the thermal shift assay (TSA) is believed to be highly unreliable, 
and not all proteins are suited to this approach. Low-affinity molecules may not lead to 
 
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a strong stabilization of a protein and hence to a non-detectable shift in protein melting 
temperature, that results in a high false-negative hit rate [34]. 
 
1.1.5.5 Other methods 

Despite the unquestionable success of the aforementioned methods, continued efforts are being 
made to develop improved techniques for detection and characterization of fragment binding. 
The MS-based analysis deserves special attention, where low affinity ligands can be identified 
by measuring the abundance of the “free” ligand in the absence and presence of the target or by 
analyzing the non-covalent protein-fragment complex in gas phase. Another particularly 
interesting ligand-detecting NMR-based method is the TINS (Target Immobilized NMR 
Screening) approach when a target is immobilized onto a resin [35]. The advantage of this 
method is that a low amount of protein is required, and it may be applied for membrane 
proteins, which are generally challenging in NMR. Calorimetric methods [36] may gain 
importance as a primary screening in fragment-based approach due to their higher sensitivity 
and throughput. The recent advances in calorimetry allows a direct measurement of enthalpy 
and entropy contributions to the binding energy, and may become an important factor in the 
selection of fragments to progress [37]. 
 
1.1.6 Elaboration of fragment hits 

The confirmed fragment hits can be readily optimized into potent leads by iterative process of 
rational design, synthesis and/or exploration of commercially available compounds that pick up 
additional target-ligand interactions. This can result in an improved affinity while still 
maintaining the drug-like properties. The process is guided by empirical information based on 
3D X-ray co-structures and binding affinity measurements. The development of fragment hits 
can follow many paths. The most important ones are the “Fragment Growth” and “Fragment 
Linking” strategies [29]. In “Fragment Growth”, high resolution crystallographic or NMR data 
is needed for the identification of close contacts between the hit and the protein of interest. 
A comparison of the binding modes and affinities is then used to infer the requirements for 
association and suggest novel fragments which may satisfy these. In parallel, the possibility of 
adding functional groups to the fragment is also examined. These modifications are directed 
towards increasing the binding affinity but at a certain point other considerations are taken 
into account such as selectivity, stability and physical properties, which are important for 
effective drug design. Fragment-growth strategies have proven particularly efficient when 
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targeting inner active site pockets, such as ATP-binding site of kinases, and allow a careful 
assessment of the effect of each new functional group or atom, thus maintaining optimal ligand 
efficiency. An example of hit improvement using this strategy is compound AT7519 developed 
by Astex [38]. It is a potent cyclin-dependent kinase 2 (CDK2) inhibitor that was successful in 
phase I clinical trials for patients with solid tumors, and has since then entered phase II studies. 
The compound elaboration started from a weak binder 1H-indazole with IC50 = 185 μM and 
LE = 0.57, and resulted in the much more potent compound AT7519 with IC50 = 0.03 μM 
and similar ligand efficiency LE = 0.40 (Figure 1.3). 
 
 
 
 
 
 
 
 
Figure 1.3 Evolution of weak fragment hit to potent drug for CDK2 as an example of “Fragment-
Growing” strategy. Adapted from [10].  
 
In the alternative “Fragment-Linking” strategy, additional screening is required in order to find 
a second fragment that can bind simultaneously with one or several fragments identified 
previously during the primary screening. In the following step, two concurrently binding 
molecules are linked in several different ways, using flexible linkers of variable length (Figure 
1.4). In binding sites composed of multiple sub-pockets, “Fragment-Linking” strategy can lead 
to a rapid increase in ligand affinity and eventually to a potent therapeutic agent. Proteases are 
ideal candidates for the “Fragment-Linking” approach. They cleave peptides or proteins, thus 
their active sites are extended with each amino acid binding in its own sub-site (S). An elegant 
example of this strategy was published by Astex [39]. A crystallography-based fragment 
screening technique was used to develop the inhibitor for the protease thrombin. Two weak 
inhibitors were identified as binding in adjacent regions, one in P1 pocket and the other in the 
P2-P4 region. High-affinity inhibitor resulted in the linkage of these two molecules, and 
crystallographic studies showed the final compound has the same binding mode as the separate 
fragments.   
1H-indazole 
IC50 = 185 μM 
LE = 0.57 
IC50 = 3 μM 
LE = 0.42 
IC50 = 97 μM 
LE = 0.39 
IC50 = 0.003 μM 
LE = 0.45 
HTC 116 cells; 
IC50 = 1.4 μM 
AT7519 
IC50 = 0.03 μM 
LE = 0.45 
HTC 116 cells; 
IC50 = 0.082 μM  
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Figure 1.4 Development of the inhibitor for thrombin protease as an example of “Fragment-Linking” 
strategy. Adapted from [40]. 
 
Both the “Fragment-Growth” and “Fragment-Linking” strategies are valuable. ”Fragment-
Growth” gives the possibility to modify the molecule in different positions and have greater 
control over the ligand size and binding efficiencies. As mentioned before, this strategy is 
generally preferred for compact active sites, which are capable of highly efficient protein-ligand 
interactions. In contrast, the “Fragment-Linking” strategy is more suited to less ligand-efficient 
and more solvent-exposed sites, which contain several sub-pockets. Although the linking 
strategy appears more elegant, the limited scope of available linkers may hinder the binding the 
original fragments. In comparison, the fragment-growing strategy provides more freedom for 
introducing chemical modifications and further optimization. 
 
1.2 Enteroviruses as a part of Picronaviridae  family 

Enteroviruses (EVs) are part of the Picornaviridae family, one of the oldest and most diversified 
families of viral pathogens of vertebrates, including humans [41]. They are small, non-
enveloped, positive-sense, single-stranded RNA viruses with an icosahedral capsid. The 
Enterovirus genus is divided into 12 species where 7 of them contain human-infecting viruses: 
EV-A, EV-B, EV-C, and EV-D, including three Rhinovirus species: RV-A, RV-B, and RV-C. 
The echovirus and coxsackievirus B (CV-B) are classified within the EV-B species and 
polioviruses (PVs) within EV-C species. EVs that infect primates, cattle and swine have also 
been described and may lead to zoonotic spread and the emergence of new human pathogens. 
The Enterovirus genus is remarkably heterogenic, with more than 250 different serotypes. 
Despite the fact that enteroviruses and rhinoviruses share numerous genetic features, 
rhinoviruses are restricted to the respiratory tract, whereas the vast majority of enteroviruses 
IC50 = 100 μM 
LE = 0.21 
IC50 = 335 μM 
LE = 0.40 
IC50 = 0.0037 μM 
LE = 0.31 
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cause gastrointestinal infections, and can spread to other organs such as the heart and the 
central nervous system. Infections caused by EVs in humans may range from asymptomatic to 
more severe illnesses manifested as encephalitis, aseptic meningitis, myocarditis, gastroenteritis, 
paralysis, poliomyelitis, with high mortality rates in infected newborn infants [42]. There are 
over five billion cases of EV infections annually worldwide and several mass outbreaks in 
Australia, United Kingdom and China have been reported [43], [44], [45]. For instance, EV-
A71 was responsible for serious complications such as encephalitis, myocarditis and deaths 
during the epidemics of hand, foot, and mouth disease in Asia in 1997, 1998, 2000, and 2008 
[46]. The disease manifestation of acute flaccid paralysis is associated with the nonpoliovirus 
EVs within the EV-B species, including the newly discovered viruses like EV-B93 [47], which 
is the subject of this thesis.  
 
1.2.1 Viral proteins 

The genome of EVs is a positive-sense, single-stranded RNA and varies between 7.4 and 7.5 kb 
with a single, large open reading frame that encodes a long polyprotein of approximately 2,200 
amino acids (~250 kDa) [48], [49]. The organization of the polyprotein follows a common 
pattern that is shared among all Picornavirus. It contains the structural proteins of the capsid, 
followed by the non-structural proteins that are involved in replication. Co- and 
posttranslational cleavage of the polyprotein occurs resulting in three precursor molecules, P1, 
P2 and P3. These are further processed releasing mature viral proteins: the structural proteins 
VP4 to VP1 from P1 and the non-structural proteins associated with replication, 2A to 2C and 
3A to 3D from P2 and P3, respectively [50] (Figure 1.5).  
 
 
 
Figure 1.5 The organization of the enteroviral polyprotein. 
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The cleavages are mediated by the viral proteases 2A and 3C/3CD protease. The 2A protease 
cleaves the bond between the P1 and P2 segments of the polyprotein, whereas the 3C protease 
and its precursor 3CD, are responsible for generating the majority of precursors and mature 
proteins [41]. The 5’ end of the genome is covalently linked to the small viral protein VPg 
[51], [52] that contains a long 5’ untranslated region (5’UTR), a 5’ terminal domain involved 
in replication and an internal ribosomal entry site (IRES) necessary for cap-independent 
translation. The typical cycle of picornavirus infection involves attachment to the specific 
receptor on the cell membrane, internalization, uncoating and releasing of RNA genome in the 
cytoplasm where it is translated by host machinery. The resulting polyprotein is then 
processed, releasing structural and non-structural proteins. The genome is replicated in 
membrane vesicles by the RNA-dependent RNA polymerase 3D, creating a negative strand 
intermediate template, which is then used for positive strand replication through the same 
mechanism. The positive RNA genome is packed into the assembled capsid to form provirion 
and released upon maturation by cell lysis (Figure 1.6). 
 
 
Figure 1.6 The enteroviral infection cycle. Adapted from [53]. 
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1.2.2 3C protease 

A typical enteroviral 3C protease is a small monomeric protein with molecular weight of 
around 20 kDa. It is considered to be the main protease due to its key role in polyprotein 
processing. In addition, the 3C protease cleaves various host proteins to alter essential cellular 
functions and facilitate virus replication [54-59]. Apart from its proteolytic activity, the 3C 
protease possesses RNA and DNA binding activities [60-64], which confirm its multitasking 
activity. Structural studies of several enteroviral (EV-A71, HRV-A2, HRV-A14, PV-1, CV-B3) 
3C proteases [64-67] have revealed an overall fold that resembles an architecture of 
chymotrypsin-like serine proteases. The proteolytic active site is located in a shallow groove 
between two topologically equivalent six-stranded β-barrels. It contains Cys-147, His-40, and 
Glu-71 catalytic triad that is linked together by a hydrogen bond network. The His-40 residue 
with help of Glu-71 and Arg-39 prepares the Cys-147 side chain for nucleophilic attack on the 
substrate’s carbonyl carbon by abstracting a proton. The role of Glu-71 is to provide 
electrostatic stabilization of the resulting positive charge on His-40, while Arg-39 neutralizes 
the charging of Glu-71 side chain. Substrate hydrolysis occurs through a covalent tetrahedral 
intermediate formed by the nucleophile from the active site (sulphur from Cys-147 side chain) 
and the carbonyl carbon of the scissile bond. The resulting oxyanion is stabilized by the 
hydrogen-bonding interactions with backbone NH groups of Cys-147, Gln-146, and Gly-145 
amino acids, which are collectively called the oxyanion hole (Figure 1.7) [65, 67]. The 3C 
protease is able to process a limited number of cleavage sites. Most cleavages occur 
preferentially between the Q↓G pair at the P1 ↓ P1’ position in peptides that consist of 
minimum 6 amino acids, and have at least 4 amino acids upstream from the scissile bond [68].  
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Figure 1.7 The mechanism of proteolysis of the EV93 3C protease. The catalytic triad (Cys-147, His-
40 and Glu-71) is shown in black. The additional amino acid (Arg-39) helping during the proteolysis 
event is shown in blue. The substrate is shown in green. The electron relays are indicated by red arrows. 
Thick dashed lines indicate strong interactions, while thin dashed lines indicate weak interactions. 
Adapted from [65]. 
 
1.2.3 Drugs targeting the 3C protease 

Enteroviral 3C proteases are highly conserved [69], and play a critical role in virus replication. 
They represent a unique class of enzymes with narrow substrate specificity, which makes them 
a promising target for antiviral therapy. Inhibitors of this enzyme are expected to possess 
a broad spectrum activity as well as high selectivity since no cellular homologue is known [70]. 
Inhibitors of proteases can be divided into two structurally distinct groups: peptidic inhibitors 
that mimic the substrate, and non-peptidic inhibitors. There are two known mechanisms of 
protease inhibition: reversible tight binding reactions and irreversible trapping reactions [71]. 
During the first mechanism, the reversible inhibitor binds to the active site of the enzyme, and 
competes with the natural peptide substrate. This inhibitor can dissociate from the enzyme in 
an unchanged form or after modification by the protease. Binding via the trapping mechanism 
leads to an irreversible protein-inhibitor reaction, which blocks the active site of the enzyme in 
a way that neither the inhibitor nor the protease can participate in further reactions. 
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1.2.3.1 Peptidic inhibitors 

The first class of inhibitors was created based on substrate specificity. Modifications of 
chemical structures have been done with the aid of 3D structures of 3C proteases alone or in 
complex with potential inhibitors in order to get molecules with higher inhibitory and antiviral 
activity (i.e. SAR studies). 
 
1.2.3.1.1 Peptide aldehydes and ketones 
 
Peptide aldehydes were one of the earliest and fairly potent inhibitors of cysteine and serine 
proteases. They bind as reversible adducts, in which the carbonyl carbon of the aldehyde forms 
a covalent bond with nucleophilic cysteine or serine resulting in stable tetrahedral species. 
Several peptidic aldehydes targeting enteroviral 3C proteases have been reported [72-76]. They 
were designed based on the knowledge that this enzyme recognizes and cuts P1-Q-P1’-G 
sequence with at least 4 amino acids upstream from the cleavage site, and possesses small non-
polar amino acid in the position P4 (Figure 1.8). It was essential to replace the amide group in 
the side chain of the glutamine in the P1 position in order to prevent from intramolecular 
cyclization with reactive terminal aldehyde group, which results in the formation of 
hemiaminal [74] (compound 1a, 1b, 2 and 3, Figure 1.8). Following a similar course of 
thought, Dragovich and colleagues synthetized ketone-containing peptidic inhibitors [77], 
which are also not able to form hemiaminals (compound 4, Figure 1.8). Both peptide 
aldehydes and ketones exhibit low micromolar antiviral activity against several rhinovirus 
serotypes, low cytotoxicity and a reasonable therapeutic index. 
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Figure 1.8 Peptide aldehydes and ketones as examples of reversible inhibitors of enteroviral 3C 
proteases. 
 
1.2.3.1.2 Michael-acceptor-based inhibitors 

More potent inhibitors against 3C proteases have been developed by introducing an electron-
withdrawing group (Michael acceptor) that replaced the scissile bond between P1-Q-P1’-G 
amino acids in the peptide-like molecules. The Michael acceptor moiety is able to bind 
irreversibly to the cysteine in the active site, forming a stable covalent complex. Hanzlik and 
co-workers [78, 79] were first to report this kind of chemical group in peptidic inhibitors for 
cysteine proteases and also later for 3C proteases.  
Additionally, a series of tripeptidic inhibitors with different Michael acceptor moieties were 
reported by scientist from Pfizer (formerly Agouron). A trans-α,β-unsaturated ethyl ester was 
1a 
1b 
2 
4 
3 
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incorporated into Cbz protected tripeptide giving a non-toxic, potent irreversible inhibitor 5 
(Figure 1.9) with moderate antiviral activity against three HRV serotypes in cell culture [80].  
 
 
 
 
 
Figure 1.9 Cbz-protected tripeptide bearing α,β-unsaturated ethyl ester moiety as an example of 
irreversible inhibitor of HRV 3C protease. 
 
Various modifications of this molecule were studied in order to enhance its antiviral activity 
[80]. The results can be summarized in a few points: 
a) Related α,β-unsaturated carboxylic acids and amides showed highly reduced inhibitory 
activity towards 3C protease, poor or no antiviral activity and increased toxicity.
b) α,β-unsaturated esters substituted in position α or cis-α,β-unsaturated esters displayed 
lower inhibitory effect when compared to the initial compound 5. 
c) Aliphatic and aryl α,β-unsaturated ketones appeared to have an increased anti-3C 
activity but possessed reduced antiviral properties and were toxic to cells. 
d) Vinyl sulfones, nitriles, phosphonates, oximes, and vinyl heterocycles exhibited low 
levels of 3C protease inhibition and were weak antiviral agents. 
e)  Michael acceptors possessing lactam, acyl oxazolidinone, and acyl urea functionalities 
demonstrated good inhibitory activity although they were inactivated by the exposure 
to non-enzymatic thiols. 
Trans-α,β-unsaturated esters emerged as the most promising inhibitors against 3C proteases. 
Due to their significant inhibitory activity, high antiviral activity, stability in the presence of 
non-enzymatic thiols, low cellular toxicity, and ease of synthesis, they were chosen for 
optimization. As a result, Pfizer (formerly Agouron) managed to obtain an excellent irreversible 
inhibitor of 3C protease rupintrivir (AG7088) with a strong antiviral capacity against broad 
spectrum of picornaviruses and low toxicity [66, 77, 81-84]. 
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1.2.3.1.2.1 Rupintrivir 

Rupintrivir (AG7088), a peptidomimetic analog, contains an α,β-unsaturated ester as 
a Michael acceptor moiety at P1’ position, a five-member lactam ring mimicking Gln at the P1 
position, a fluoro-phenylalanine and a methylene group instead of the backbone amide in the 
P2 position and an 5-methyl-3-isoxazole group at the P4 position (compound 6, Figure 1.10). 
Rupintrivir as a highly specific molecule against picornaviral 3C proteases demonstrated no 
activity towards cellular serine and cysteine proteases. It was shown that AG7088 is potent 
antiviral compound in vitro against all tested HRV and EV clinical isolates and it was selected 
for clinical trials [69, 84, 85]. Due to poor oral bioavailability, rupintrivir was administrated 
intranasally [86], and appeared to be well tolerated, reduce the severity of illness and viral load 
in HRV challenge trials [87, 88]. However, in naturally infected patients, rupintrivir was not 
able to considerably affect the virus load or reduce the severity of disease, thus was halted from 
further clinical studies [89].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Rupintrivir and compound 1 – irreversible, highly-specific inhibitors against enteroviral 3C 
protease. 
 
 
P1’ 
P3 
P2 
P1 
P4 
6 – rupintrivir 
7 – compound 1 
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1.2.3.1.2.2 Compound 1 

Since rupintrivir did not show the desirable therapeutic effect, several modifications were 
introduced to improve its efficacy. Compound 1 (AG7404), the orally bioavailable analogue of 
rupintrivir with similar mechanism of action was synthetized [89, 90] (compound 7, Figure 
1.10). Compound 1 also displayed broad spectrum anti-HRV activity, and was safe and well-
tolerated during phase I clinical trials. However, its subsequent clinical development of 
AG7404 was also discontinued [89]. 
 
1.2.3.1.3 Other peptidic inhibitors 

Despite the fact that the most promising drug candidates: rupintrivir and compound 1 failed 
in clinical development, α,β-unsaturated esters or terminal aldehydes still play a major role in 
enteroviral drug discovery. Many peptide-like molecules with Michael acceptor moiety were 
described in recent years as promising and potent drugs, including anti-coxsackievirus B3 [91-
93], anti-EV-A71 [94, 95], anti-EV-D68 and anti-PV [95] 3C protease inhibitors. 
Furthermore, there are many other peptide-based inhibitors designed for combating enteroviral 
3C proteases such as azapeptides [96, 97], diazomethyl ketones [98], S-nitrosothiols [99], 
tripeptidil α-ketoamides [100]. 
 
1.2.3.2 Non-peptidic inhibitors 

In order to develop orally available 3C protease inhibitors with more favorable 
pharmacokinetic properties, a series of reversible non-peptidic compounds was explored. α,β-
unsaturated ketobenzamides and mono-, di- and tri-substituted benzamides appeared to 
possess good inhibitory property against HRV 3C protease [101, 102] (compound 8 and 9, 
Figure 1.11).  
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Figure 1.11 α,β-Unsaturated ketobenzamide 8 and 5-substituted benzamide 9. 
 
A combination of structure-based design, molecular modelling, and structure-activity 
relationship analysis led to the discovery of 2,3-dioxindole-based reversible HRV inhibitors 
(isatins). Despite their high affinity for the protease pocket, this class of compounds were 
lacking antiviral activity and were very toxic, most probably due to the high electrophilic 
reactivity [103] (compound 10, Figure 1.12).  
 
 
 
 
 
 
 
 
Figure 1.12 Isatin 10, benzoquinone 11 and antraquinone 12. 
 
Compounds with quinone moiety and quinone analogs were described as useful inhibitors of 
cysteine proteases including caspases and 3C proteases [Patent WO-02076939]. The 
compounds 11 and 12 (Figure 1.12) tested against several HRV showed moderate in vitro 
8 
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activity. The mechanism of action is based on the assumption that quinone-like molecules act 
as Michael acceptors and are prone to attack by cysteine residue.  
A blind screening revealed that homophthalimides are promising anti-HRV compounds with 
certain antiviral activity [104, 105]. MS analysis suggested that representative compound of 
this class forms a tight binding complex with 3C protein (compound 13, Figure 1.13). 
The ability of heteroaromatic esters to inhibit HRV 3C proteases was recently described [106]. 
The best molecule 14, active also against SARS 3CL protease and HAV 3C protease, was 
modified resulting in similarly potent inhibitor with 4-quinolone moiety (compound 15, 
Figure 1.13). 
 
 
 
 
 
 
 
 
 
Figure 1.13 Homophtalimide 13 and heteroaromatic esters 14 and 15. 
 
High-throughput screening of a small molecule library led to the discovery of several novel 
pyrazole-based inhibitors active towards SARS-CoV 3CL protease. One of them (compound 
16, Figure 1.14) equally inhibited both the 3C protease and 3CL protease from PV and CoV, 
respectively. Further development of this compound gave a molecule 17 inhibiting various 
3C(L) proteases with low μM IC50 values, including SARS-CoV 3CL protease, CoV-229E 
3CL protease, CV-B3 3C protease, EV-A71 3C protease, and HRV-A14 3C protease [107]. 
 
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Figure 1.14 Pyrazole-based compounds. 
 
Another series of molecules pseudoxazolones appeared to be potent time-dependent inhibitors 
of HAV and HRV 3C protease at micromolar levels (compound 18, Figure 1.15) [108, 109]. 
However, their reactivity towards thiols (e.g. DTT) does not allow them to be a drug 
candidate. 
Since previously mentioned non-peptidic HRV 3C protease inhibitors, like isatines and 
homoftalimides, have suffered from cellular toxicity and average antiviral activity, a new class 
of low-molecular Michael acceptor-containing, irreversible HRV inhibitors was developed 
[110]. The selection of the core molecule was done based on the previously described potent 
peptidomimetic inhibitors such as rupintrivir. A small molecule with α,β-unsaturated ethyl 
ester and lactam moiety was used for high-throughput synthesis of large number of potential 
active compounds. The best inhibitors (molecule 19, Figure 1.15) were highly active against 
HRV14, possessed good antiviral properties and were non-toxic to cells. 
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Figure 1.15 Pseudoxazolone 18 and Michael acceptor-containing small molecule 19. 
 
It is worth mentioning microbial fermentation extracts as a source of antiviral inhibitors. Anti-
HRV molecules include naphtoquinonelactol [111], a quinine like citrinin [112], radicinin 
[112], and triterpene sulfates [113]. 
 
1.2.3.3 Non-covalent inhibitors 

All previously mentioned inhibitors possess electrophilic functionality that forms reversible or 
irreversible covalent interaction with the reactive cysteine (Cys-147) in the active site. Despite 
its high potency and selectivity, there is an increased risk of additional reactions with host 
proteins due to the electrophilic nature of the compounds.  There is only one class of inhibitors 
mentioned in the literature that were proven by X-ray crystallography and NMR not to bind 
covalently to the enteroviral 3C protease [114]. 2-Phenylquinolone (compound 20, Figure 
1.16) was selected through fragment-based screening, and appeared to be an effective non-
covalent binder of HRV 3C protease with IC50 = 0.2 μM. A couple of analogs were studied in 
order to improve their inhibitory activity (compound 21 with IC50 = 10 nM) and solubility 
(compound 22 with IC50 comparable to the compound 20). The results showed that 
compound 18 binds to the P1 pocket in the proteolytic active site of the 3C protease. 
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Figure 1.16 Non-covalent inhibitors of HRV 3C protease. 
 
Researchers have to face several challenges to develop antiviral agents to treat infections caused 
by enteroviruses. Firstly, there are more than 250 different serotypes within the Enterovirus 
genus, which render vaccine development impractical. Secondly, to make a drug effective, good 
oral bioavailability and tissue distribution are essential to reach sufficient drug quantity at the 
infected site. Furthermore, the treatment for acute viral infections must be administrated at 
a proper time for an optimal effect. Since most of the symptoms occur within 3 days of illness, 
the drug must be capable of reducing the severity of symptoms within the first 24 hours. 
Finally, the drug must have an excellent safety profile to ensure an appropriate risk/benefit 
ratio. To date, numerous anti-enteroviral agents have been identified to target the 3C protease, 
which is highly conserved among different serotypes. Unfortunately, none of the described in 
the literature compounds fulfilled all aforementioned requirements to be considered a safe and
effective drug. Thus, there are no EV-specific antivirals on the market, which have been 
approved by the FDA. That is why it is essential to continue the development of drugs for 
enteroviral infections.  
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The objectives of this thesis were: 
 
1. Structural and functional characterization of EV-B93 3C protease.  
The study involved: protein expression and purification, activity evaluation in the proteolytic 
activity assay, protein crystallization, determination of the crystal structure, and functional 
interpretation of the results. 
2. Structural and biochemical characterization of potent irreversible inhibitors rupintrivir and 
compound 1 in complex with EV-B93 3C protease.  
The study involved: protein-inhibitor complex preparation, inhibitory activity evaluation in 
the proteolytic activity assay, complex crystallization, determination of the complex crystal 
structure, and interpretation of the results. 
3. Structural and biochemical characterization of small irreversible inhibitors NZO, NZN and 
DB5_60 in complex with EV-B93 3C protease. 
The study involved: protein-inhibitor complex preparation, inhibitory activity evaluation in 
the proteolytic activity assay, complex crystallization, determination of the complex crystal 
structure, and interpretation of the results. 
4. Discovery of new non-covalent inhibitors against EV-B93 3C protease and its further 
biochemical, antiviral, and structural characterization. 
The study involved: STD NMR based fragment screening, hit validation using Thermofluor 
and SPR, hit optimization and its further activity evaluation in the proteolytic activity assay 
and antiviral assay, complex preparation and crystallization, determination of the complex 
crystal structure, bioinformatics simulations of binding mode, interpretation of the results. 
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3.1 Materials  

This section lists the materials, instruments and common techniques used throughout the 
study. All reagents for media and buffer preparation were purchased from Merck, Fluka, 
Sigma, Panreac, Invitrogen, Roche, BioRad and Fermentas. 
 
3.1.1 Expression vector 

The protein was expressed using the below characterized vector (Table 3.1). 
Table 3.1 Expression vector used in the study. 
vector type pDEST, Gateway T7 Vectors 
cloning method Gateway® 
promoter T7 
protein tag HisTag (6x) 
antibiotic resistance ampicillin 
  
3.1.2 Plasmid purification 

Plasmid purification was performed with the Qiagen Miniprep kit (Qiagen) on a table-top 
centrifuge following the manufacturer’s guidelines. 
 
3.1.3 Growth media 

 Luria-Bertani (LB) medium: 1 % [w/v] tryptone, 0.5 % [w/v] yeast extract, 1 % NaCl 
 Autoinduction medium [115] 
stock solutions: 
1 M MgSO4  
1000x Trace Metals (1L): 8 ml 5 M NCl, 5 g FeCl2·4H2O, 184 mg CaCl2·H2O, 64 mg 
H3BO3, 18 mg CoCl2·6H2O, 4 mg CuCl2·2H2O, 340 mg ZnCl2, 605 mg 
Na2MoO4·2H2O, 40 mg MnCl2·4H2O 
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50x 5052 (200 ml): 25 % [v/v] glycerol, 2.5 % [w/v] glucose, 10 % [w/v] lactose 
50x M (250 ml): 1.25 M Na2HPO4·2H2O, 1.25 M KH2PO4, 2.5 M NH4Cl, 0.25 M 
Na2SO4 
400 ml of autoinducing media contains: 4 g tryptone, 2 g yeast extract, 380 ml MiliQ water, 
800 μl 1 M MgSO4, 800 μl 1000x Trace Metals, 8 ml 50x 5052, 8 ml 50x M, and was 
supplemented with 400 μl of each antibiotic and 4 ml pre-culture. 
 LB agar plates: 1 % [w/v] tryptone, 0.5 % [w/v] yeast extract, 1 % NaCl, 1.5 % [w/v] 
agar 
 Antibiotics: ampicillin (stock solution: 100 mg/ml in MiliQ water, working 
concentration: 100 μg/ml); chloramphenicol (stock solution: 35 mg/ml in 100 % [v/v] 
ethanol, working concentration: 35 μg/ml) 
 
3.1.4 Bacterial  cloning and expression strains 
 
Bacterial cloning and expression strains used in the study are listed in Table 3.2. 
Table 3.2 Cell  strains used in the study. 
cell  strain genotype remarks 
DH5α  F- endA1 glnV44 thi-1 recA1 
relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, 
hsdR17(rK- mK+), λ- 
Cloning strain. Novagen 
Rosetta (DE3) F- ompT hsdSB(RB- mB-) 
gal dcm λ(DE3 [lacI lacUV5-
T7 gene 1 ind1 sam7 nin5]) 
pLysSRARE (CamR) 
Expression strain with DE3, 
and pLysSRARE. 
pLysSRARE contains tRNA 
genes argU, argW, ileX, glyT, 
leuW, proL, metT, thrT, 
tyrU, and thru. Novagen 
 
3.1.5 Transformation of bacterial  strains 

Transformations were performed with competent Escherichia coli cells obtained through the 
calcium chloride-method [116]. Competence was induced by heat-shock treatment at 42 °C 
for 45 s.  
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3.1.6 Protein electrophoresis 

Protein electrophoresis (SDS-PAGE) was carried out using BioRad electrophoresis tanks and 
power sources applying currents that ranged between 150 V-250 V. Obtained stained gels were 
subsequently scanned. Reagents for gel preparation, running and staining are detailed below: 
 15 % SDS PAGE-gel: separative gel (15 % [w/v] acrylamide, 0.4 % [w/v] bis-
acrylamide, 0.1 % [w/v] SDS in 0.38 M Tris pH 8.8), concentrative gel (6 % [w/v] 
acrylamide, 0.16 % [w/v] bis-acrylamide, 0.1 % [w/v] SDS in 0.13 M Tris pH 6.8. 
Polymerization occurred in the presence of 0.06 % [v/v] cross-linking reagent 
N,N,N’,N’-tetramethylethylenediamine (TEMED) and 0.05 % [w/v] initiator 
ammonium persulfate (APS). 
 running buffer (0.025 M Tris, 0.2 M Glycine, 0.05 % [w/v] SDS)  
 loading buffer (55 mM Tris pH 6.8, 1.6 % [w/v] SDS, 8.3 % [v/v] glycerol, 0.002 % 
[w/v] Bromophenol Blue, 5 % [v/v] β-mercaptoethanol) 
 molecular weight markers: SeeBlue (Invitrogen) 
 Coomasie staining solution (0.5 % [w/v] Coomassie Blue G-250 (Sigma), 50 % [v/v] 
methanol, 10 % [v/v] acetic acid) 
 Coomasie destain  solution (10 % [v/v] acetic acid, 10 % [v/v] isopropanol) 
 
3.1.7 Chromatography columns 

Protein purification and peptide analysis columns were purchased from GE Healthcare and 
were used on ÄKTA Purifier systems (GE Helathcare). Protein purification and peptide 
analysis protocols were carried out using the following materials: 
 HisTrap HP column (5 ml) 
 Superdex 75 column (10/300) 
 Superdex 75 column (16/60) 
 SOURCE™ 5RPC ST 4.6/150 
 SOURCE™ 15RPC ST 4.6/100 



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3.1.8 Protein concentration 

Protein concentration was carried out with Vivaspin (GE Helathcare) and Amicon (Merck 
Millipore) devices of different sizes (0.5 ml, 2 ml, 4 ml, 6 ml, 20 ml) with different cut-off 
values (3000, 10000 MWCO). 
Protein concentration was measured on a Nanodrop 2000 device (Thermoscientific). 
Protein purity was assessed by analyzing the SDS-PAGE gels, gel filtration chromatograms and 
MS spectra. 
 
3.1.9 Mass spectrometry 

MALDI-TOF Mass Spectrometry (MS) analysis was performed in the Proteomics Platform of 
Barcelona Science Park. 
 
3.1.10 Protein crystall ization 

Reagents and crystallization materials were purchased from Hampton Research and Molecular 
Dimensions. Crystallization experiments were performed at the Crystallography Platform of 
Barcelona Science Park.  
The crystals screens used in this study are listed in Table 3.3. 
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Table 3.3 Crystal screens used in the study. 
code screen # of conditions reference 
PAC1 Crystal Screen I 
Crystal Screen II 
48 
48 
Hampton Research 
PAC2 Wizard I 
Wizard II 
48 
48 
Emerald Bio 
PAC3 Index 96 Hampton Research 
PAC4 Salt RX 96 Hampton Research 
PAC15 JBS1 
JBS2 
JBS3 
JBS4 
24 
24 
24 
24 
Jena Bioscience 
PAC16 JBS5 
JBS6 
JBS7 
JBS8 
24 
24 
24 
24 
Jena Bioscience 
PAC17 JBS9 
JBS10 
Clear Strategy I – 8.5 
Clear Strategy II – 8.5 
24 
24 
24 
24 
Jena Bioscience 
Molecular Dimensions 
PAC21 PACT premier HT-96 96 Molecular Dimensions 
PAC22 Pi-PEG Screen 96 Jena Bioscience 
PAC23 Pi – minimal screen 96 Jena Bioscience 
 Midas 96 Molecular Dimensions 
 Morpheus 96 Molecular Dimensions 
 
Crystallization experiments were performed using the sitting or hanging drop vapor diffusion 
method. 
Initial screens were performed in 96-well sitting drop MRC plates. Crystallization screenings 
were prepared with Tecan robots (Tecan). Crystallization drops were handled by Cartesian 
(Cartesian Technologies) and Crystal Phoenix robots (ArtRobbins), both providing microscale 
liquid handling for high-throughput crystallization screening. The best conditions were 
optimized on 24-well Linbro plates (Hampton Research). Particular conditions and settings are 
indicated for every experiment in following sections. 
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3.1.11 X-ray data collection, processing and structure determination 

X-ray data collection was performed in the European Synchrotron Radiation Facility (ESRF, 
Grenoble, France) at the beamlines ID23-2, ID14-4, ID29 and the ALBA synchrotron 
(Cerdanyola de Vallès, Spain) at the beamline XALOC. 
Diffraction data were indexed and integrated using XDS [117], and scaled and merged with 
SCALA [118]. Structure elucidation and refinement were carried out using the CCP4 suite of 
programs [119]. The initial phases were obtained by molecular replacement using PHASER 
[120] with previously-generated EV-B93 3C structure as a model (PDB code: 3Q3X). 
REFMAC [121] was employed for structure refinement and Coot [122] for interpretation of 
electron density and model building. Geometry restraint information for covalent ligands was 
generated with SKETCHER within CCP4. 
 
3.1.12 Saturation transfer difference NMR screening 

STD-NMR screening was performed at the PCB NMR facility within collaboration with the 
group of Ernest Giralt (IRB Barcelona, Spain). STD-NMR spectra were acquired on a Varian 
Inova 500 MHz spectrometer with 5 mm PFG Penta Probe equipped with automatic sample 
changer (S/N for 1 H was 815:1 (0.1% ethylbenzene in CDCl3)) at 25 °C. The data were 
analyzed with MestreNova software. 
All common materials and instruments needed for the NMR experiment were provided by the 
laboratory of Ernest Giralt. Specific deuterated chemicals were purchased from cortecnet, 
Deutero GmbH, euriso-top. 
Fragment library consisted of 527 compounds mixed in a cocktails of 5 was designed and 
prepared by Michael Goldflam in the laboratory of Ernest Giralt (IRB Barcelona, Spain). 
 
3.1.13 Thermal shift assay 

Thermal shift assay (TSA) measurements were carried out in an iCycler iQ Real Time PCR 
Detection system (BioRad). Data evaluation and melting point determination were performed 
using BioRad Optical System Software.  
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3.1.14 Surface plasmon resonance experiment 

Surface plasmon resonance (SPR) analysis was performed at the Scientific and Technological 
Centers, University of Barcelona, Spain). SPR experiments were carried out on a Biacore T100 
instrument (GE Healthcare) with the use of Series S Sensor Chip CM5 (GE Healthcare). The 
data were analyzed with BiaEvaluation 1.1 software (GE Healthcare) and Scrubber 2.0 
software (BioLogic). 
All common materials needed for the SPR experiment were provided by the Cytometry Unit. 
Amine Coupling Kit and His Capture Kit were purchased from GE Helathcare. 
 
3.1.15 Cell-based proteolytic assay and antiviral assay 

Cell-based proteolytic assay [123] and antiviral assay were performed by Rachel Ulferts (prof. 
Frank van Kuppeveld’s laboratory, Utrecht University, The Netherlands).  
 
3.1.16 Analogs selection, docking and classical molecular dynamics 
simulations  

Bioinformatics calculations including analogs selection, docking and classical molecular 
dynamics (MD) simulations were performed by Daniel Álvarez (Xavier Barril’s laboratory, 
University of Barcelona, Spain). Analogs selection was performed through the sub-structural 
similarity search in the in-house database or ZINC database using SMILE/SMART definitions 
and BABEL software. Docking was performed using rDOCK software and classical MD 
simulations were prepared using pyMDMix (http://mdmix.sourceforge.net/) and run with 
AMBER software.  
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3.2 Methods  

This section lists the materials and methods selected and designed for the purpose of this work 
and used throughout the study. 
 
3.2.1 Construct design 

The construct of EV-B93 3C protease was designed and prepared by Bruno Coutard 
(Architecture et Fonction des Macromolécules Biologiques, Marselle, France). The 3C protease 
gene was cloned into a pDEST14 expression vector with an N-terminal MK and C-terminal 
His6 tag. 
The C147A mutant of EV-B93 3C protease was previously obtained via site-directed 
mutagenesis. The protein was expressed and purified by Lionel Costenaro (IBMB-CSIC, 
Barcelona). 
 
3.2.2 Plasmid transformation 

1 μl of the plasmid DNA containing the sequence for the EV-B93 3C protease was mixed with 
50 μl of competent cells. The mixture was incubated 30 min. on ice and then briefly heated to 
42 °C during 45 s. The mixture was placed back on ice for 2 min and 500 μl of LB medium 
was added. The cells were incubated in 37 °C for 1 h and plated out for marker selection. 
 
3.2.3 Protein expression 
 
EV-B93 3C protein expression was performed in Rosetta E. coli cells. Two flasks filled with 
150 ml LB medium each were used for pre-cultures preparation. To each flask one colony of 
freshly transformed bacteria and two antibiotics ampicillin and chloramphenicol were added. 
The flasks were incubated overnight at 37 °C at 220 rpm agitation speed. The cultures were 
grown in 2 l flasks containing 750 ml of autoinduction media supplemented with two 
antibiotics ampicillin and chloramphenicol. The cells were initially incubated at 37 °C for 3 h 
with 220 rpm agitation speed and then the temperature was lowered to 16 °C. The induction 
time was 24 h. Cells were harvested at 7000 rpm, and cellular pellet was frozen in -20 °C. 
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3.2.4 Protein purification 
 
Ni-NTA affinity purification and gel filtration 
Cell pellet coming from the large scale cultures was resuspended in the lysis buffer (50 mM 
Tris pH 8.0, 200 mM NaCl, 30 mM imidazole, 2 mM β-mercaptoethanol) supplemented 
with Complete Protease Inhibitor Cocktail Tablets (Roche) (1 tablet/50 ml) and 0.75 mg/ml 
DNase I. The cells were lysed using cell disruptor (PECF Constant Systems Ltd.) and 
centrifuged at 13000 rpm or 24000 rpm. The supernatant was filtered and loaded on the pre-
equilibrated HisTrap HP column. Column was washed with 15 CV of binding buffer (50 mM 
Tris pH 8.0, 200 mM NaCl, 30 mM imidazole, 2 mM β-mercaptoethanol) and eluted with 
elution buffer (50 mM Tris pH 8.0, 200 mM NaCl, 500 mM imidazole, 2 mM β-
mercaptoethanol) in a 20 CV linear gradient from 30 to 500 mM imidazole. Eluted fractions 
from the affinity column were concentrated and loaded on the Superdex 75 (16/60) column. 
Protein was eluted with 1.3 CV gel filtration buffer (10 mM Tris pH 8.0, 200 mM NaCl, 
2 mM DTT). All above steps were performed at 4 °C. Collected fractions were flash frozen in 
liquid nitrogen and stored in -20 °C. 
The C147A mutant of EV-B93 3C protease was previously produced, purified, flash-frozen in 
liquid nitrogen and stored in -20 °C by Lionel Costenaro (IBMB-CSIC, Barcelona). 
 
3.2.5 Reductive methylation 
 
1250 ml of 4.4 mg/ml EV-B93 3C protease solution was used for buffer exchange (50 mM 
Hepes pH 7.4, 10 mM NaCl) using PD-10 Desalting Column (GE Helathcare). Resulting 
solution was concentrated to volume of 1.3 ml and transferred to a 2 ml tube with a small 
stirring bar. 20 μl of freshly prepared 1M DMAB (Fluka) was added followed by 40 μl 1M 
methanol-free formaldehyde (Thermo Scientific). Mixture was incubated for 2h with gentle 
stirring. 20 μl of 1M DMAB and 40 μl of 1M formaldehyde were added, and the mixture was 
left for additional 2h. The final aliquot of 10 μl 1M DMAB was added and the reaction 
mixture was left overnight. Finally, 80 μl of 1M glycine was added and stirred for 1 h. The 
protein solution was repurified on Superdex 75 10/300 column using 1.3 CV of the elution 
buffer (10 mM Tris pH 8.0, 200 mM NaCl, 8 mM DTT). All steps were performed at 4 °C. 
 
 
 

Materials and Methods 

 
56 
3.2.6 In vitro  proteolytic activity assay 
 
100 μl of reaction mixture containing 1.9 μM 3C protease, 25 μM substrate peptide, 5 % 
DMSO, buffer (30 mM Tris pH 8.0 and 50 mM NaCl or 50 mM HEPES pH 7.4 and 
50 mM NaCl) and (optionally) different concentrations of inhibitor (ranging from 0 to 
350 μM) was incubated in 37 °C during 3 h or 20 h. The reaction was quenched by addition 
of 0.5 % (final concentration) trifluoroacetic acid (TFA). Samples were analyzed by reverse-
phase high-performance liquid chromatography (HPLC) on SOURCE™ 5RPC ST 4.6/150 or 
SOURCE™ 15RPC ST 4.6/100 column using: 2 % to 90 % linear gradient of acetonitrile in 
0.1 % TFA  
The 3C protease activity in the absence of inhibitor was defined as 100 %. 
The following peptides (GL Biochem) were dissolved in DMSO at a concentration of 5 mM 
and used for testing 3C proteases activity (Table 3.4). 
 
Table 3.4 Peptide sequences used for testing various 3C proteases. 
protease peptide sequence 
EV-B93 3C Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2 
EV-B93 3C (C147A) Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2 
ERBV-1 3C Ac-AKDGGIFAQ↓SRDRHYLVGTV-NH2 
HRV-A49 3C Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2 
EV-D68 3C Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2 
AiV 3C Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2 
PSV 3C Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2 
 
3.2.8 Crystall ization  

3.2.8.1 Protein sample preparation 

The protein solution coming from the purification step was centrifuged at 14500 rpm for 
10 min.  
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3.2.8.2 Protein-covalent compound complex preparation 

2.0-2.8 mg/ml protein solution containing a 2-fold molar excess (for rupintrivir and 
compound 1) or 12-fold molar excess (for NZN, NZO and DB5_60) of compound were 
incubated overnight in 20 °C (rupintrivir, compound 1) or 30 °C (NZN, NZO and DB5_60). 
The mixture was loaded on the Superdex 75 (10/300) column and protein was eluted using 
1.3 CV of the buffer (10 mM Bicine pH 8.5, 300 mM NaCl, 1 mM DTT for 
rupintrivir/compound 1 and 10 mM Tris pH 8.0 100 mM NaCl for DB5_60). The collected 
fractions were concentrated to 2.3-3.2 mg/ml. 
Rupintrivir and compound 1 were provided by Pfizer, while NZO, NZN and DB5_60 were 
synthesized by Daniel Becker (Jörg Rademann’s laboratory, Freie Universität Berlin, 
Germany). All compounds were dissolved in DMSO at concentrations of 0.5 mM 
(rupintrivir), 50 mM (compound 1) or 100 mM (NZO, NZN and DB5_60). 
 
3.2.8.3 Protein-non-covalent compound complex preparation 

1.5-5.0 mg/ml protein solution was incubated with 5, 10 or 20-fold molar excess of compound 
and (optionally) with equal amount of peptide substrate in room temperature for 0.5 h. 
The compounds from the screening library were dissolved in a mixture of deuterated 
DMSO:H2O (9:1 ratio) at a concentration of 100 mM, while the analogs (purchased from 
Enamine, Ambinter, FCH or synthesized by Daniel Becker) were dissolved in DMSO at 
concentrations of  12.5 mM, 50 mM or 100 mM. 
 
3.2.8.4 Crystall ization screening and optimization 

Crystallization trials were performed as indicated in Materials section 3.1.10 at 20 °C. Drops 
were prepared by mixing 150 μl of protein solution with 150 μl of reservoir solutions. Crystal 
optimization was performed manually with 1+1 μl sitting drops. 
All the conditions and PAC screens, which were used in protein and protein-complex 
crystallization are listed below (Table 3.5) 
 
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Table 3.5 Protein or protein/complex crystall ization screening conditions. 
protein/complex excess of 
compound 
additive concentratio
n [mg/ml] 
temperatu
re [°C] 
screen 
EV-B93 3C - - 2.3 20 
PAC1-4, 
PAC15-17, 
PAC21-23, 
Midas, 
Morpheus 
EV-B93 3C 
(methylated) 
- - 4.7 20 PAC1-4 
EV-B93 3C – 
rupintrivir 
2x - 2.5 20 PAC1-4 
EV-B93 3C – 
compound 1 
2x - 3.2 20 PAC1-4 
EV-B93 3C – 
NZN 
12x - 2.4 20 PAC1-4 
EV-B93 3C – 
NZO 
12x - 2.3 20 PAC1-4 
EV-B93 3C – 
DB5_60 
12x - 2.3 20  
EV-B93 3C – 164, 
188, 290, 306, 484, 
544 
20x - 5.0 20 
PAC1-4, 
PAC15-17 
EV-B93 3C –EN2, 
EN12 
10x - 1.5 20 PAC1-4 
EV-B93 3C –EN2, 
A4 
20x - 2.9 20 PAC1-4 
EV-B93 3C –A4 5x - 2.9 20 PAC1-4 
EV-B93 3C –A4 5x 
peptide 
substrate 
(1x) 
2.3 20 PAC1-4 
EV-B93 3C –A4_D 5x, 20x 
peptide 
substrate 
(1x) 
2.3 20 PAC1-4 
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3.2.8.5 Soaking experiment 

2 μl drops with previously prepared crystals of native protein were soaked for 10 s, 10 min, 
1 day or 3 days before freezing with non-covalent compound by addition of 0.5 μl of its 
50 mM or 100 mM DMSO solution.  
 
3.2.8.6 Mounting and freezing crystals 

Protein crystals were fished with nylon cryoloops, and immediately soaked in solutions 
containing reservoir solution supplemented with 25 % of glycerol, MPD or PEG400 and 
(optionally) with appropriate non-covalent compound at a final concentration of 25 mM or 
50 mM. Cryoprotected crystals were flash frozen in liquid nitrogen. 
 
3.2.9 Saturation transfer difference NMR 

Buffer exchange for the EV-B93 3C protease was performed using PD-10 Desalting Column 
(GE Helathcare). The deuterated buffer for saturation transfer difference NMR (STD NMR) 
contained 30 mM Tris-d11 and 50 mM NaCl in deuterated water (99.8 %) at pH 8.0. 
Samples of 600 μl were prepared in an 3 mm NMR tube and contain 10 μM EV-B93 3C 
protease, 500 μM of each compound, 10 μM DSS, 30 mM Tris pH 8.0 and 50 mM NaCl 
with the total concentration of DMSO below 3 %. In the case the spectrum contained STD 
signals, the covalent inhibitor rupintrivir was added to the mixture reaching the final 
concentration of 20 μM and additional STD-NMR experiment was performed. 
The 1H NMR spectra were acquired with presat water suppression and 32 increments. For 
STD-NMR experiments a pulse sequence with water suppression by the Watergate technique 
[124] was selected and 1,024 increments were recorded. The length of the mixing time to 
remove residual protein signals was set to 10 ms. Saturation time was set to 2.5 ms and the 
relaxation delay to 2 s. On and off resonance frequency for EV-B93 3C protease were 0 and 35 
ppm. All spectra were recorded using an 8000 Hz spectral width. 
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3.2.10 Thermal shift assay 

The aliquots were prepared on ice in a 96-well PCR plates (Bio-Rad) sealed with optically clear 
PCR sealers (Bio-Rad) and contain 12.2 μM EV-B93 3C, 30 mM Tris pH 8.0, 50 mM NaCl 
and 42x Sypro Orange protein gel stain (Invitrogen). Then compounds dissolved in DMSO 
were added at a final concentration of 1 mM. For the control sample the same volume of 
DMSO were added to reach final concentration of 5 %. Samples were heated from 20 °C to 
95 °C at a rate of 0.5 °C/min, and the change in absorbance (λex = 490 nm; λem = 575 nm) was 
monitored over time in an iCycler iQ Real Time PCR Detection System (Bio-Rad).  
 
3.2.11 Surface plasmon resonance 

Running buffer containing 10 mM Tris 8.0, 100 mM NaCl and 5 % of DMSO was used. The 
EV-B93 3C protease was amine coupled (EDC/NHS, Amine Coupling Kit) using a 10 mM 
NaAc pH 6.0 as a coupling agent. Immobilization level was ranging from 1,700 to 2,050 RU. 
For the protein captured via its His-tag, firstly the antibody was covalently immobilized on the 
sensor chip (EDC/NHS, His Capture Kit) using a 10 mM NaAc pH 4.5 as a coupling agent at 
10,000 RU. Then the protein was captured with the immobilization level around 1,900 RU.  
The stock solutions of used compounds were taken from the screening library. Concentration 
series (1.0, 0.5, 0.25, 0.125 and 0 mM) were prepared in the running buffer in a 96-well plate 
(Greiner Bio-One) and sealed (GE Healthcare). The flow rate was 30 μl/min. Test substances 
were injected at 20 °C with a contact time of 60 s and dissociation time of 180 s. The new 
portion of protein was coupled every 5 measurements. 

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4.1 Structural and functional studies of EV-B93 3C protease  

Expression and purification of native EV-B93 3C protease and its C147A mutant were 
performed in order to characterize them biochemically and structurally. Preparation of C147A 
mutant was aimed at investigating the importance of the Cys-147 residue in the proteolytic 
activity of the enzyme. The Cys-147, a member of a putative catalytic triad, was replaced by 
Ala-147. Large amount of native EV-B93 3C protease was needed for subsequent fragment 
screening and testing of possible hits. The C147A mutant was previously expressed and 
purified by Lionel Costenaro (IBMB-CSIC). 
 
4.1.1 Expression and purification of native EV-B93 3C protease 

The protein was expressed in E. coli cells and then purified using Ni-NTA affinity column and 
gel filtration. IMAC (Immobilized Metal ion Affinity Chromatography) purification provided 
two elution peaks (Figure 4.1 A, left side). The first one was very small and corresponds to the 
fractions giving multiple bands in SDS-PAGE gel (Figure 4.1 A, right side). The second peak, 
much higher than the first one, corresponds to the fractions giving broad bands in SDS-PAGE 
gel (Figure 4.1 A, right side). The collected fractions from the second peak were concentrated 
and loaded on the gel filtration column. The protein appeared as a single peak (Figure 4.1 B, 
left side) which corresponds to pure, highly concentrated 3C protease (Figure 4.1 B, right 
side). The molecular mass of the protein eluted during both purification steps corresponds to 
the mass of monomeric EV-B93 3C protease of 21.3 kDa. The purification yield was ~ 25 mg 
per liter of cell culture. The presence of EV-B93 3C protease was confirmed by MS-MS 
fragmentation.  
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Figure 4.1 Purification of EV-B93 3C protease. (A) Chromatogram from IMAC purification and 
corresponding SDS-PAGE gel. (B) Chromatogram from gel filtration and corresponding SDS-PAGE 
gel. Green line corresponds to imidazole gradient, blue line to absorbance at 280 nm, red line to 
absorbance at 260 nm and black bar indicates fractions collected and loaded on the SDS-PAGE gel. 
 
 
4.1.2 Biochemical characterization of native EV-B93 3C protease and its 
C147A mutant 
 
The proteolytic activity of EV-B93 3C protease and its C147A mutant was tested in the in 
vitro assay with the use of peptide substrate (Ac-RHSVGATLEALFQ↓GPPVYREIKIS-NH2) 
that mimics 2C↓3A cleavage site present in the enteroviral polyprotein (Figure 4.2).  
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Figure 4.2 In vitro proteolytic activity assay of EV-B93 3C protease (A) and its C147A mutant (B). 
Reverse-phase chromatograms show in red the products of the digestion of the peptide (Ac-
RHSVGATLEALFQ↓GPPVYREIKIS-NH2) by EV-B93 3C protease and its C147A mutant. 
Chromatograms of the peptide substrate alone are shown in blue. 
 
The reverse phase HPLC analyses of the overnight incubations of the peptide with EV-B93 3C 
protease revealed the presence of expected cleavage products and the protein. The results were 
confirmed by MALDI-TOF MS (Matrix Assisted Laser Desorption Ionization Time-of-Flight
Mass Spectrometry) for the cleavage substrate and the products (Figure 4.3 B, C, D), and for 
the protein (Figure 4.3 A). The proteolytic activity assay performed with the C147A mutant of 
EV-B93 3C protease showed no effect on the substrate, since no cleavage products were 
observed; thereby confirming that presence of the Cys-147 is critical for the proteolytic activity 
of EV-B93 3C protease. 
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Figure 4.3 MALDI-TOF mass spectra of native EV-B93 3C protease (A), cleavage peptide products (B 
and C) and peptide substrate (D). 
 
 
4.1.3 Crystall ization screening and crystal optimization of native EV-B93 3C 
protease 
 
The active and native EV-B93 3C protease was subjected to crystallization screening which 
resulted in many conditions containing thin needle-like crystals, a couple of rod-like crystals 
and only one with octahedron-like crystals. The most promising conditions were chosen for 
further optimizations. The best crystal conditions and corresponding crystal data are 
summarized in Table 4.1. 
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Table 4.1 EV-B93 3C protease crystall ization conditions and the corresponding 
crystal data. 
PAC 
initial  
condition 
optimized 
condition 
crystal 
shape 
resolution 
[Å] 
space 
group 
cell  
dimension 
PAC1 
B6 
20 % PEG8000 
0.2 M Mg(Ac)2 
0.1 M sodium 
cacodylate pH 
6.5 
18 % PEG8000 
0.2 M Mg(Ac)2 
0.1 M sodium 
cacodylate pH 
6.0 
 
1.90 P21 
a=38.90 
b=64.62 
c=66.27 
β=90.90 
PAC22 
A9 
15 % PEG2000 
0.1 Tris pH 8.0 
12 % PEG2000 
0.1 Tris pH 8.0 
 
1.57 P21 
a=38.95 
b=56.94 
c=84.62 
β=94.99 
PAC4 
F10 
1.5 M LiSO4 
0.1 M NaAc pH 
4.6 
1.5 M LiSO4 
0.1 NaAc pH 5.6 
 
2.70 P65 
a=135.9 
b=135.9 
c=51.57 
PAC1 
C8 
2M (NH4)2SO4 2M (NH4)2SO4 
 
2.70 P65 
a=123.27 
b=123.27 
c=102.63 
 
 
The protein in the presence of PEGs was crystallizing in the monoclinic P21 space group and 
was able to give high-resolution diffraction data (below 2 Å). The crystals obtained in the 
acidic conditions and/or the presence of sulfates appeared to be of lower resolution (2.70 Å) 
and belong to the hexagonal P65 space group. The crystals grown in 18 % PEG8000, 0.2 M 
Mg(Ac)2 and 0.1 M sodium cacodylate pH 6.0 were very thin and susceptible to radiation 
damage, which may have had an impact on the resolution (1.90 Å). However, the crystals 
obtained in 12 % PEG2000 and 0.1 Tris pH 8.0 were thicker and more resistant, which led to 
the improvement in the data resolution (1.57 Å). 
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4.1.4 Structure determination of EV-B93 3C protease and data analysis 
 
Many data sets of different EV-B93 3C protease crystals were collected and then solved with 
molecular replacement (see Materials and Methods section) using previously obtained structure 
of EV-B93 3C protease as a search model (PDB code: 3Q3X). This model structure has 
inactivating the enzyme oxidized cysteine residue in the active site, which was also observed in 
many data sets collected within this study. However, it was possible to obtain a few EV-B93 
3C protease structures with no or partial oxidation. It is believed that the oxidation occurs 
during crystallization or X-ray data collection, since the purified protein is active in vitro (see 
4.1.2 section). The selected structure of EV-B93 3C protease was refined at 1.6 Å to a final 
Rwork of 16.2 % and Rfree of 19.6 % (see Table 4.2 for data collection and refinement statistics). 
It was possible to model all residues except the His6 tag and the last two and one C-terminal 
residues for chains A and B, respectively. The Ramachandran plot shows 96.06 % of the 
residues to be in the preferred regions, while 3.66 % and 0.28 % in the allowed and the outlier 
regions, respectively. The asymmetric unit contains two molecules that are related by a non-
crystallographic 2-fold axis. The refined structure has 208 water molecules and 2 glycerol 
molecules. 
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Table 4.2 Data collection and refinement statistics for EV-B93 3C protease 
native crystal.  
parameter EV-B93 3C protease 
resolution range [Å] 84.30-1.57 (1.61-1.57) 
space group P21 
cell dimensions [Å, °] a=38.95 b=56.94 c=84.62 β=94.99 
no. of observed reflections 164878 
no. of unique reflections 51255 (3742) 
completeness [%] 99.31 (99.4) 
mean multiplicity 3.2 (3.3) 
Rmerge 0.074 (0.498) 
<I>/σ<I> 10.06 (2.01) 
Rwork 0.162 
Rfree 0.196 
no. of protein atoms (non-H) 3111 
no. of water molecules 208 
no. of hetero compounds 2 glycerol molecules 
RMSD for bond length [Å] 0.022 
RMSD for bond angles [°] 2.038 
mean B value [Å2] 15.391 
Ramachandran analysis: 
preferred/allowed/outliers [%] 
96.06/3.66/0.28 
Values in parenthesis correspond to the outer resolution shell.  
       , where   is the ith-intensity measurement of reflection h 
and    is the average intensity for multiple measurements. 
 and        .  was calculated for 5% of the reflections not used for 
refinement. 
 
EV-B93 3C protease folds into two antiparallel β-barrels that are orientated 90° apart, linked 
by a 20-amino-acid loop containing a short α-helix and flanked by other two α-helixes at the 
N- and C-termini of 14 and 3 amino acids long, respectively. The two barrels are topologically 
equivalent and are formed by six antiparallel β strands (Figure 4.4).  
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Figure 4.4 Crystal structure of EV-B93 3C protease. (A) Ribbon representation of the two molecules 
present in the asymmetric unit with the non-crystallographic 2-fold axis perpendicular to the plane. 
The protease folds into two antiparallel β-barrels, forming the chymotrypsin-like fold. The catalytic 
triad is highlighted as stick representations. (B) Active site of EV-B93 3C protease. Key residues are 
highlighted as stick representation. Oxyanion hole formed by the main-chain amides of Cys-147, Gln-
146 and Glu-145 is indicated as a blue dot. 
 
 
The structure confirms that EV-B93 3C protease adapts a chymotrypsin-like fold similarly to 
other picornavirus 3C proteases. The active site is placed in the shallow cleft between the two 
barrels and is made of a nucleophilic Cys-147 coming from the C-terminal barrel and the acid-
base pair His-40 and Glu-71 located in the N-terminal barrel. There are two conformations of 
the His-40, one corresponds to the catalytically competent form where the sulfur atom from 
the Cys-147 is in plane with the imidazole ring from the His-40 and the carboxylate group of 
the Glu-71. In the second conformation the His-40 is rotated about 120° and exposed to the 
solvent. Substrate hydrolysis occurs through an attack of the active-site nucleophilic Cys-147 
onto the carbonyl carbon of the scissile bond. The resulting covalent tetrahedral transition state 
is stabilized by the oxyanion hole formed by the amides of the main chain residues: Cys-147, 

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Gln-146 and Gly-145. In the structure the oxyanion hole is occupied by a water molecule that 
interacts with the amide of Cys-147 or Gln-146. EV-B93 3C protease like the other 3C 
proteases recognizes amino acid residues in the close proximity to the cleavage site, mostly at 
the P4, P3, P2, P1 and P1’ positions that fit into the corresponding specific binding sub-sites 
(S4, S3, S2, S1 and S1’). The comparison of the HRV-A14 3C protease structure covalently 
bound to a peptide (Ac-LEALFQ-ethyl propionate) inhibitor containing the P6 to P1 sub-side 
residues [125], with EV-B93 3C protease allowed the proposal of the possible substrate 
binding pocket of EV-B93 3C protease. The active site is formed by the residues belonging to 
the β strands A1, A3, and A4 and the loop containing the amino acids that make the oxyanion 
hole. 
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4.2 Rupintrivir and compound 1 as covalent inhibitors of EV-B93 
3C protease 

4.2.1 Biochemical characterization of rupintrivir and compound 1 inhibitory 
activity 
 
Rupintrivir and its orally bioavailable analogue compound 1 were developed as irreversible 
inhibitors of 3C protease from HRV and EV species [84, 89] (Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Chemical structure of rupintrivir (AG7088) and its orally bioavailable analogue compound 1 
(AG7404). Asterisks indicate carbon atoms that make an irreversible covalent bond with the active-site 
cysteine residue of EV-B93 3C protease. 
Since the proteolytic active site is highly conserved within Enterovirus species, both compounds 
should bind as well to EV-B93 3C protease. In order to verify it, the inhibitory effect of each 
antiviral agent was tested in the in vitro proteolytic activity assay (Figure 4.6).  
 
 
 
 
 
rupintrivir (AG7088) 
compound 1 (AG7404) 
* 
* 
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Figure 4.6 Inhibition of the in vitro proteolytic activity of EV-B93 3C protease by rupintrivir. Reverse-
phase chromatograms show in red the products of the digestion of the peptide (Ac-
RHSVGATLEALFQ↓GPPVYREIKIS-NH2) by EV-B93 3C protease (p) without rupintrivir (r) (A), 
with rupintrivir at 1:3 inhibitor-to-protein ratio (B) with equimolar ratio rupintrivir to protein (B) and 
with rupintrivir at 30:3 inhibitor-to-protein ratio (D). Chromatograms of the peptide substrate alone 
are shown in blue. 
 
 
The native EV-B93 3C protease was incubated with three different inhibitor-to-protease molar 
ratios in the presence of the peptide substrate. The reverse-phase HPLC analyses showed that 
both rupintrivir and compound 1 efficiently inhibited EV-B93 3C protease in vitro (the results 
obtained for compound 1 are not shown, since they were very similar to those obtained for 
rupintrivir). No cleavage products were detected with the equimolar and 10-fold excess of the 
inhibitors over the enzyme (Table 4.3). These results are consistent with the prior statements 
regarding the potency and irreversible inhibition of these compounds towards 3C proteases 
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from HRVs and EVs [84, 89], and confirm their strong antiviral effect against broad spectrum 
of enteroviruses. 
 
Table 4.3 Cleavage efficiencies of the peptide substrate by EV-B93 3C 
protease . 
inhibitor inhibitor-to-protein molar 
ratio 
relative activity RAi 
- 0:3 100 
rupintrivir 1:3 100 
 3:3 0 
 30:3 0 
compound 1 1:3 100 
 3:3 0 
 30:3 0 
i relative activity is defined as the efficiency of a proteolytic reaction in the presence of inhibitor divided 
by the efficiency of the proteolytic reaction in the absence of inhibitor multiply by 100 %. 
 
 
4.2.2 Crystall ization screening and crystal optimization of EV-B93 3C 
protease in a complex with rupintrivir and compound 1  
 
In order to characterize the molecular interactions of rupintrivir and compound 1 with EV- 
B93 3C protease, the previously purified protein was incubated with both inhibitors. After the 
purification with the use of size exclusion chromatography, the protein solutions were used in 
the crystallization screenings. Many crystal hits for both complexes appeared. They were 
containing the thin needle-like crystals (for both compounds), the rhombohedron-like crystals 
(for rupintrivir) and the rod-like and rhombohedron-like crystals for the complex with 
compound 1. In the both cases the rhombohedron-like crystals were chosen for further 
optimizations. The best crystal conditions and corresponding crystal data are summarized in 
Table 4.4. 
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Table 4.4 Crystall ization conditions and corresponding crystal data for EV-B93 3C 
protease in complex with rupintrivir and compound 1. 
 PAC initial  
condition 
optimized 
condition 
crystal shape resolution 
[Å] 
space 
group 
cell  
dimension 
rru
pi
nt
ri
vi
r 
PAC2 
E3 
 
20 % 
PEG8000 
0.2 M MgCl2 
0.1 M Tris 
pH 8.5 
25 % 
PEG8000 
0.25 M MgCl2 
0.1 M Tris pH 
8.5 
 
1.50 P21 
a=39.00 
b=63.91 
c=66.36 
β=90.43 
cco
m
po
un
d 
1 
PAC4 
E4 
 
2.4 M 
(NH4)HPO4 
0.1 M Tris 
pH 8.5 
1.8 M 
(NH4)HPO4 
0.1 M Tris pH 
8.3  
1.32 P21 
a=39.04 
b=64.45 
c=68.74 
β=90.81 
 
 
4.2.3 Structure determination of EV-B93 3C protease in complex with 
rupintrivir and compound 1 and data analysis 
 
The structure of both complexes: EV-B93 3C protease-rupintrivir and EV-B93 3C protease-
compound 1 were solved with molecular replacement using previously obtained structure of 
EV-B93 3C protease as a search model (PDB code: 3Q3X). Both complexes of EV-B93 3C 
protease with rupintrivir and compound 1 were crystallizing in the monoclinic P21 space group 
giving the high-resolution diffraction data of 1.50 Å and 1.32 Å, respectively. The structures 
were refined to a final Rwork of 16.6 % and Rfree of 19.8 % for the complex with rupintrivir and 
to Rwork of 12.5 % and Rfree of 17.0 % for the complex with compound 1 (see Table 4.5 for 
refinement statistics). The final model for EV-B93 3C protease-rupintrivir and for EV-B93 3C 
protease-compound 1 encompasses all amino acids except the first N-terminal and the last 
three C-terminal (including His6 tag) residues. One molecule of rupintrivir and one molecule 
of compound 1 per protein chain were unequivocally and precisely defined for the complexes 
of EV-B93 3C protease with rupintrivir and compound 1, respectively. In the both cases the 
asymmetric unit contains two protein molecules. The refined structure of EV-B93 3C 
protease-rupintrivir has 375 water molecules, 2 Mg2+ ions and 1 Cl- ion, while the refined 
structure of EV-B93 3C protease-compound 1 has 543 water molecules, 8 ethylene glycol 
molecules, 3 HPO42- ions and 2 NH4+ ions. 
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Table 4.5 Data collection and refinement statistics for EV-B93 3C protease-
rupintrivir and EV-B93 3C protease-compound 1 complex crystals.  
parameter EV-B93 3C protease-
rupintrivir 
EV-B93 3C protease-
compound 1 
resolution range [Å] 30.0-1.50 (1.55-1.50) 39.0-1.32 (1.39-1.32) 
space group P21 P21 
cell dimensions [Å, °] a=39.00 b=63.91 c=66.39 
β=90.43 
a=39.04 b=64.45 c=68.74 
β=90.81 
no. of observed reflections 194865 268892 
no. of unique reflections 52513 (5196) 79978 (11666) 
completeness [%] 100 (100) 100 (100) 
mean multiplicity 3.7 (3.6) 3.4 (3.3) 
Rmerge 0.063 (0.488) 0.085 (0.508) 
<I>/σ<I> 17.7 (2.5) 5.2 (1.5) 
Rwork 0.166 0.125 
Rfree 0.198 0.170 
no. of protein atoms (non-H) 3011 3322 
no. of water molecules 375 543 
no. of hetero compounds 2 rupintrivir molecules, 2 Mg2+ 
ions, Cl- ion 
2 compound 1 molecules, 
8 ethylene glycol 
molecules, 3 HPO42- ions, 
2NH+ ions 
RMSD for bond length [Å] 0.008 0.012 
RMSD for bond angles [°] 1.41 1.60 
mean B value [Å2] 12.21 9.29 
mean B value for inhibitor 
molecules [Å2] 
16.8, 22.0 20.2, 19.7 
Ramachandran analysis: 
preferred/allowed/outliers [%] 
97.26/2.74/0.0 89.1/9.6/1.3 
PDB accession code 3RUO 3Q3Y 
Values in parenthesis correspond to the outer resolution shell.  
        , where   is the ith-intensity measurement of reflection h 
and    is the average intensity for multiple measurements. 
 and        .  was calculated for 5% of the reflections not used for 
refinement. 
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The electron density allowed for the precise building of one molecules of rupintrivir and 
compound 1 per protein. In the both cases, the electrophilic β-carbon (Figure 4.5, asterisk) is 
covalently bound to the Cys-147 active site after its Michael addition, forming a stable 
tetrahedral adduct and resulting in an irreversible inactivation of the protease. Rupintrivir 
binds to EV-B93 3C protease in a partially extended conformation with its peptidomimetic 
backbone making antiparallel β-sheet-type hydrogen bonds with the part of the solvent-
exposed β strand, A4, of the protein. The P1’ carbonyl oxygen of the ethyl ester is placed above 
the oxyanion hole formed by the amide groups of the Cys-147, Gln-146, Gly-145 but makes a 
hydrogen bond only with the latter (Figure 4.7). The P1 part of rupintrivir is deeply inserted 
between the β-strand A4 and the loop formed by the Thr-142, Arg-143 and Ala-144. The P1 
lactam ring interacts with the Thr-142 and His-161, mimicking the recognition site for 
glutamine, which is highly conserved in the 3C cleavage sequences. The P2 1-fluorobenzen-4-
yl ring forms a stacking interaction with the His-40 and Glu-71 and its fluorine atom interacts 
with the Thr-130, Arg-39 and Leu-127. The valine side chain from the P3 part is solvent 
exposed, thus does not interact with the protein. The P4 part of rupintrivir lies in a deep 
groove formed by the β-strands A4, A3 and A1 and interacts with the protein residues Leu-
125, Gly-128, Asn-165, Glu-168 and Phe-170. 
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Figure 4.7 Refined structure of EV-B93 3C protease in complex with rupintrivir. The inhibitor is 
represented as sticks, with its 2Fo-Fc-weighted electron density contoured at 1.0 σ and represented as a 
blue mesh. EV-B93 3C protease residues interacting with rupintrivir are shown as sticks and are 
labeled. 
 
 
The binding mode of compound 1 to EV-B93 3C protease is very similar to that of rupintrivir 
(Figure 4.8). The differences between the two antivirals lie in the least-conserved P2 and P3 
positions. In the P2 position the 1-fluorobenzen-4-yl group is substituted by the 2-propynyl 
residue, which stacks between the His-40, Glu-71 and Leu-127. In the case of the P3 position, 
the valine residue is replaced by the ring, which makes two main-chain hydrogen bonds with 
the Gly-163 and Gly-164.  
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Figure 4.8 Refined structure of EV-B93 3C protease in complex with compound 1. The inhibitor is 
represented as stick, with its 2Fo-Fc-weighted electron density contoured at 1.0 σ and represented as 
blue mesh. EV-B93 3C protease residues interacting with compound 1 are shown as sticks and are 
labeled. 
 
 
Rupintrivir generates slightly more interactions with the binding pocket of EV-B93 3C 
protease than compound 1, thus should exhibit higher potency. Indeed, rupintrivir appeared to 
inhibit EV-B93 replication in infected RD cells with a mean EC50 of 33 nM, while the EC50 
for compound 1 was 93 nM [126]. 
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Figure 4.9 Multiple sequence alignment of 3C proteases for 11 enteroviruses representing the currently 
known species diversity of the Enterovirus genus (without Enterovirus F). The sequence names indicate 
the names and accession IDs of the viruses, and the corresponding species are indicated at the ends of 
the sequences. Invariant residues are white with a red background; conserved residues are shown in red 
font. The residues involved in the interactions are marked below as green and magenta bars for 
rupintrivir and compound 1, respectively. Catalytic residues Cys-147, His-40 and Glu-71 are indicated 
by violet asterisks.  
 
A noticeable feature of the binding pocket is the conservation of EV-B93 3C protease residues 
interacting with rupintrivir and compound 1 within all 11 enterovirus species representing the 
entire genetic diversity of this genus (except Enterovirus F). Most of the residues are identical 
or physico-chemically similar (Figure 4.9). The results with EV-B93 3C protease indicate that 
these compounds may be valuable antivirals against other enteroviral species. The high level of 
conservation among EVs of the residues forming the 3C protease binding pockets for 
rupintrivir and compound 1, and the broad-spectrum antiviral activity of these compounds in 
vitro reinforce their potential as excellent candidates for developing potent antivirals against all 
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EVs [91]. The process of the optimization of rupintrivir and compound 1 should be 
continued, since in the studies to control natural rhinovirus infection by 3C protease 
inhibitors, both inhibitors showed unsatisfactory performance and were therefore excluded 
from further clinical development [127]. The analysis of multiple alignment also suggests that 
the level of conservation of the residues forming the substrate binding pocket can be useful in 
the process of designing novel antiviral compounds against new emerging enteroviruses. 
 
4.3 Small  covalent inhibitors of EV-B93 3C protease as a starting 
point for development of potent drugs 

Despite the failure of rupintrivir and compound 1 in clinical trials, it is worth developing new 
covalent binders of enteroviral 3C proteases. Instead of optimizing already existing inhibitors, 
the new covalent low-molecular inhibitors may be selected through the screening of 
commercial or in-house designed libraries. The hits will bind with a high probability to the S1 
sub-site of 3C protease due to its close proximity to the nucleophilic cysteine in the active site. 
When the binding is confirmed, the compound may serve as a starting point for further 
development. The compound may grow into adjacent pockets, resulting in a more potent 
inhibitor. The same path was followed by the collaborators from Freie Universität in Berlin. 
They were succeeded in selecting a series of low-molecular compounds able to inhibit 3C 
protease from CV-B3. Three molecules were sent to us for functional and structural studies 
with EV-B93 3C protease, a very close analog of CV-B3 (97 % identity). 
 
4.3.1 Biochemical characterization of NZN, NZO and DB5_60 inhibitory 
activity 
 
Chemical synthesis of three low-molecular-weight compounds was done by Daniel Becker 
from Freie Universität Berlin (Germany). They were designed to be irreversible covalent 
inhibitors of enteroviral 3C proteases. These inhibitors possess a P1/P1’ – Michael-acceptor 
moiety, which is an α,β-unsaturated esther (NZO), an α,β-unsaturated amide (NZN) or a 
vinyl sulfonate esther (DB5_60), which can covalently link to the Cys-147 in the active site. 
They may exist in two tautomeric forms: hydroxypyrazol and pyrazolone structure (Figure 
4.10). 
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Figure 4.10 Chemical structures of three potentially irreversible inhibitors of EV-B93 3C protease. The 
compounds remain in the tautomeric equilibrium of hydroxypyrazol form (on the left side of each 
equilibration) and pyrazolone form (on the right side of each equilibration). 
 
 
The stability of each compound was determined in two different buffers (30 mM Tris pH 8.0; 
50 mM NaCl and 50 mM HEPES pH 7.4; 50 mM NaCl). NZO, NZN and DB5_60 were 
diluted in each buffer and loaded on the reverse-phase HPLC column: immediately or after 3h-
incuabtion in 37 °C. The chromatograms showed that the NZO compound was not stable in 
neither of the buffers while the NZN molecule appeared to be more stable in HEPES buffer. 
In the case of the sulfonate esther DB5_60 the compound was stable in both conditions 
(Figure 4.11). Since all previous experiments were performed in Tris buffer, it was chosen for 
further activity tests. 
 
 
 
 
 
NZO 
NZN 
DB5_60 
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Figure 4.11 Stability of NZO, NZN and DB5_60 compounds in Tris buffer pH 8.0 and HEPES 
buffer pH 7.4. Chromatograms of compounds before incubation are shown in blue and after 3h-
incubation at 37 °C are shown in red. The concentration of each compound was 50 μM. 
 
 
In order to test the inhibitory activity of the NZO, NZN and DB5_60 compounds, the in 
vitro proteolytic activity assays were performed. Native EV-B93 3C protease was incubated 
with three different inhibitor-to-protease molar ratios in the presence of the peptide substrate. 
For the compounds NZO and NZN both buffers were used while in the case of the DB5_60 
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compound the reactions were performed only in Tris buffer. The obtained results are gathered 
in Table 4.6. 
 
Table 4.6 Cleavage efficiencies of substrate peptide by EV-B93 3C protease. 
buffer inhibitor inhibitor-to-
protease ratio 
relative activity 
RA [%] 
30 mM Tris pH 8.0 
50 mM NaCl 
- 0:1 100 
NZO 1:1 0 
1:3 0 
1:10 0 
NZN 1:1 ~60 
1:3 ~30 
1:10 0 
DB5:60 1:1 0 
1:3 0 
1:10 0 
50 mM HEPES pH7.4 
50 mM NaCl 
- 0:1 100 
NZO 1:1 8 
1:3 5 
1:10 0 
NZN 1:1 ~90 
1:3 ~80 
1:10 ~60 
DB5_60 1:1 ndi 
1:3 nd 
1:10 nd 
ind – not determined 
 
Despite the fact that the NZO compound was less stable than the NZN molecule, it showed 
better inhibitory activity in both buffers. It may be due to higher reactivity of α,β-unsaturated 
esther moiety which on the other hand is more susceptible to hydrolysis when compared to 
α,β-unsaturated amide functionality. The most stable compound DB5_60 showed very good 
inhibitory activity. According to the literature [128] vinyl sulfones are 10-fold more reactive 
than α,β-unsaturated esther-based inhibitors against human rhinovirus 3C protease. They may 
react not only with the cysteine active side but also modify nonspecifically amino acid side 
chains in proteins. 
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4.3.2 Crystall ization screening and crystal optimization of EV-B93 3C 
protease in complex with NZO, NZN and DB5_60 
 
Native EV-B93 3C protease was incubated with a 12-fold molar excess of each compound 
(NZO, NZN and DB5_60). After purification with the use of size exclusion chromatography, 
the protein samples were used for crystallization screening. Previous trials with lower amount 
of the NZO and NZN compounds did not succeeded in producing protein-complex crystals. 
The DB5_60 compound was insoluble in high concentration and caused the precipitation of 
the protein. For that reason higher amount of the protein was used to get enough protein for 
the crystallization purpose. Crystallization screenings resulted in many conditions with the 
needle-like crystals (for all three compounds) and several conditions with the rectangular-like 
crystals (for the NZO and NZN molecules). Both needle-like and rectangular-like crystals were 
used for further optimization (Figure 4.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Crystallization of EV-B93 3C protease with NZN compound: initial condition (A) and 
after optimization (B); with NZO compound (C) and with DB5_60 compound (D).
 
 
The crystals of EV-B93 3C protease-NZO complex were instable and difficult to optimize. 
Usually both types of the crystals (the needle-like and the rectangular-like) grew together which 
hampered the fishing process. The complex of NZN and EV-B93 3C protease gave well-
defined large crystals, which were easy to handle. Precipitation of EV-B93 3C protease 
occurred in the presence of DB5_60 most probably due to unspecific covalent modification of 
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the protein with highly hydrophobic moieties. The protein that did not precipitate after 
incubation with DB5_60 is believed to stay unmodified, since it crystallized only in the needle-
like form. The best crystal conditions were summarized in Table 4.7.  
 
 
Table 4.7 Crystall ization conditions and corresponding crystal data for EV-B93 3C 
protease in complex with NZO, NZN and DB5_60. 
 PAC initial  
condition 
optimized 
condition 
crystal 
shape 
resolution 
[Å] 
space 
group 
cell  
dimension 
NN
Z
O
 
PAC3 
G7 
 
25 % PEG3350 
0.2 M NH4Ac 
0.1 M Bis-Tris 
6.5 
16 % PEG3350 
0.2 M NH4Ac 
0.1 M Bis-Tris 
6.0 
 
1.86 P21 
a=57.28 
b=51.92 
c=59.28 
β=103.69 
NN
Z
N
 
PAC3 
G7 
 
25 % PEG3350 
0.2 M NH4Ac 
0.1 M Bis-Tris 
6.5 
20 % PEG3350 
0.2 M NH4Ac 
0.1 M Bis-Tris 
6.0 
 
1.73 P21 
a=57.46 
b=52.33 
c=62.27 
β=103.73 
DD
B
5_
60
 
PAC4 
C7 
3.5 M sodium 
formate 
0.1 M Bis-Tris 
propane pH 7.0 
2.4 M sodium 
formate 
0.1 M Bis-Tris 
propane pH 7.0 
 
2.85 P21 
a=39.03 
b=57.30 
c=84.84 
β=94.43 
 
 
4.3.3 Structure determination of EV B93-3C protease in a complex with NZN  
 
Many data sets were collected for the crystal complexes of EV-B93 3C protease and the NZO, 
NZN and DB5_60 molecules. Only one crystal structure showed the presence of additional, 
however incomplete, electron density in the active side of only one protein molecule in the 
asymmetric unit. The structure of EV-B93 3C protease-NZN complex was solved at 1.73 Å 
using previously obtained structure of native EV-B93 3C protease as a search model (PDB 
code: 3Q3X). The complex was crystallizing in the monoclinic P21 space group with the cell 
parameters different from the ones obtained for the complexes with rupintrivir and 
compound 1. The structures were refined to a final Rwork of 16.1 % and Rfree of 20.1 % (see 
Table 4.8 for refinement statistics). The final model for the EV-B93 3C protease-NZN 
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complex contains all amino acids except the last two C-terminal (including His6 tag) residues. 
The asymmetric unit has two protein molecules A and B, where in the chain B one molecule of 
NZN was defined. The refined structure of the EV-B93 3C protease-NZN complex contains 
255 water molecules. 
 
Table 4.8 Data collection and refinement statistics for EV-B93 3C protease-
NZN complex crystals.  
parameter EV-B93 3C protease-NZN 
resolution range [Å] 60.49-1.73 (1.77-1.73) 
space group P21 
cell dimensions [Å, °] a=57.46 b=52.33 c=62.27 β=103.73 
no. of observed reflections 121071 
no. of unique reflections 36869 (2654) 
completeness [%] 97.86 (97.1) 
Mean multiplicity 3.3 (3.3) 
Rmerge 0.052 (0.724) 
<I>/σ<I> 13.35 (2.05) 
Rwork 0.161 
Rfree 0.201 
no. of protein atoms (non-H) 3101 
no. of water molecules 255 
no. of hetero compounds 1 NZN molecule 
RMSD for bond length [Å] 0.02 
RMSD for bond angles [°] 2.033 
mean B value [Å2] 31.6 
mean B value for inhibitor molecules [Å2] 67.2 
Ramachandran analysis: 
preferred/allowed/outliers [%] 
96.35/2.81/0.84 
Values in parenthesis correspond to the outer resolution shell.  
       , where   is the ith-intensity measurement of reflection h 
and    is the average intensity for multiple measurements. 
 and        .  was calculated for 5% of the reflections not used for 
refinement. 
 
 
The quality of the electron density was sufficient to build one molecule of NZN in the chain B 
of the asymmetric unit. In the chain A the additional electron density in the active site was very 
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poor, therefore the placement of the NZN compound failed. As a result of a Michael addition, 
the electrophilic β-carbon of the NZN compound (Figure 4.10, arrow) was covalently linked 
to the nucleophilic Cys-147, forming a stable tetrahedral adduct. The NZN molecule is 
inserted between the solvent-exposed β-strand, A4, and the loop formed by the Thr-142, Arg-
143 and Ala-144 and occupies the S1 and S1’ sub-pockets of the protein (Figure 4.13 A and 
B). The P1’ carbonyl oxygen of the ethyl amide is oriented towards the oxyanion hole and 
makes a hydrogen bond with the amide groups of the Cys-147, Gln-146 and Gly-145. The 
interaction between ethyl amide group of the NZN compound and the His-40 from the 
catalytic triad of the protein is mediated by a water molecule. The nitrogen atom from the P1-
amide bond interacts with the Arg-143, Gly-164 and a water molecule that mediates the 
interaction with the His-161. Plausible hydrogen bonds were identified between the P1-
heterocyclic ring and both the Gly-164 and Thr-142 as well as a water molecule that supports 
the interaction with the Ala-144. Additionally, delocalized electrons from the P1-heterocyclic 
ring make the π-π interaction with the peptide bond of the Arg-143 – Ala-144 on the one side 
and the Gly-164 – Asn-165 on the other one. The cycloheptane moiety from the P1 part is 
solvent exposed, thus does not interact with the protein. The third amino acid from the 
catalytic triad Glu-71 is not involved in the binding of NZN. 
 
 
Figure 4.13 Refined structure of EV-B93 3C protease in complex with NZN. The inhibitor is 
represented as sticks, with its 2Fo-Fc-weighted electron density contoured at 1.0 σ and represented as 
black mesh. EV-B93 3C protease residues in close proximity to NZN compound are labeled. Water 
molecules are represented as red spheres. (A) top view, (B) side view. 
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The electron density corresponding to the NZN compound is not fully defined and suggests a 
weaker binding to the protein when comparing with rupintrivir and compound 1. It is not 
surprising since NZN is twice smaller molecule (598 Da and 320 Da for rupintrivir and NZN, 
respectively) and occupying only two sub-pockets of the active site, generates substantially 
fewer interactions with EV-B93 3C protease. Better defined electron density of the NZN 
compound is observed for the regions with more intramolecular interactions, i.e. the covalent 
bonding with the Cys-142, the interaction of the carbonyl oxygen with amides from the 
oxyanion hole and the heterocyclic ring with its hydrogen bonds and the π-π interactions. On 
the other hand, the ethyl group from the NZN amide bond, two carbon atoms from the 
central part the molecule and the cycloheptane residue have the least visible electron density 
suggesting its high flexibility. Additionally, the interaction between the oxygen atom from the 
heterocyclic ring of the NZN compound and both the Thr-142 hydroxyl group from the side 
chain and the Thr-142 carbonyl oxygen from the main chain does not allow the prediction 
which tautomer hydroxypyrazol or pyrazolone is the most likely form to interact with the 
protein.  
 
The NZN compound is small and can serve as a starting point for further modifications. There 
is not much space for additional alterations of the molecule in the S1 pocket. However, there is 
an empty space below the internal amide bond, which is occupied by a water molecule and 
mediates the interaction with the His-161 of EV-B93 3C protease. Introduction of a 
hydrogen-acceptor moiety in this position may result in an increase of the NZN affinity. The 
growth of the molecule towards the P2 pocket can be problematic, since the most suitable for 
the modification carbon atom (β carbon from the α,β-unsaturated amide moiety) is a part of 
the reactive double bond. An additional substitution in this position may result in the 
reduction of the reactivity due to a steric hindrance. It is also possible to substitute the ethyl 
residue from the α,β-unsaturated amide moiety by a more bulky group, thus enlarge the 
molecule towards the P1’ sub-pocket and subsequently improve the NZN potency. 
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Figure 4.14 Proteolytic active site of EV-B93 3C protease alone (A) and in complex with NZN (B), 
rupintrivir (C) and compound 1 (D). Protein surface is colored according to the electrostatic potentials 
with red and blue indicating negative and positive charges, respectively. Inhibitors are represented as 
sticks: yellow for NZN, grey for rupintrivir and green for compound 1. The sub-pockets of the active 
sites are labeled. 
 
 
The structure of the unliganded EV-B93 3C protease is similar to that of in complex with the 
covalent inhibitors. However, the S2 sub-pocket appeared to be more flexible which can be 
clearly noticed in the complex with rupintrivir (Figure 4.14 C). Upon binding of this antiviral, 
the S2 sub-pocket gets tighter, supporting its accommodation in the active site. In the case of 
the structures of the native protein and in the complex with NZN and compound 1, the S2 
region remains open. This suggests its relative malleability towards different types of residues 
A 
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that can be present in the position P2 (Figure 4.14 A, B and D). The same observation was 
also noticed in the case of 3C proteases from EV-A71 and CV-A16, where the S2 position is 
able to accommodate more variation in amino acid residues [129]. In contrast, the P1, P3 and 
P4 sub-pockets retain its shape within the studied structures, which may suggest more stringent 
structural requirements towards the size of accepted residues in the corresponding sub-pockets.  
 
The electrostatic surface of EV-B93 3C protease active site is generally maintained upon 
binding of the low molecular weight NZN inhibitor, while after attachment of the larger 
compounds, rupintrivir or compound 1, it changes mainly in the S2 sub-pocket. The positively 
charged S1 cavity seems to be the most conserved region within the whole substrate-biding site, 
since its electrostatic surface does not change much between unbound and bound forms. The 
high conservation of the S1 region was previously observed [81], thus confirming the above-
mentioned statement. 
 
Covalent modification of EV-B93 3C protease by irreversible inhibitors led to the structures 
with a relatively higher resolution when comparing to the structures of the native protein. This 
happens due to tighter, more compact folding of the enzyme in bound state. For EV-B93 3C 
protease this relation is not so evident, but becomes clearer in the case of the other homologous 
3C proteases within enteroviral species. For example EV-A71 3C protease alone gave the 
structure at 2.99 Å-resolution, while the same protein in complex with rupintrivir formed 
crystals that diffracted up to 1.0 Å [65]. Similar observations were described for EV-D68, CV-
B3 and polio virus 3C proteases [64, 65, 95, 130]. 
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4.4 Discovery of non-covalent inhibitors of EV-B93 3C protease 
using fragment-screening methodology 

Almost all known inhibitors of enteroviral 3C proteases, cited in the literature to date, possess 
electrophilic moiety that forms a covalent interaction with the cysteine in the active pocket. 
Despite its high potency and selectivity, there is a possibility of additional modifications of host 
proteins which may lead to cell toxicity. In order to avoid side reactions caused by reactive 
electrophilic groups, non-covalent inhibitors of enteroviral 3C proteases should be found. The 
aim of this study was to identify the first non-covalent modulators of EV-B93 3C protease, 
which will be able to efficiently inhibit its protease activity. 
The use of fragments in a discovery of enzyme inhibitors usually involves four steps: 
preparation of a fragment library, screening of fragments, validation of hits using biophysical 
methods and elaboration of the best molecules. In this study the fragment library was already 
prepared and was used directly to perform the STD NMR screening followed by the 
competitive STD NMR screening with the use of covalent inhibitor rupintrivir. The best hits 
were validated with a thermal shift assay (TSA) and a surface plasmon resonance (SPR). The 
most promising compounds were then characterized biochemically in the proteolytic activity 
assay. In parallel crystallization experiments were carried out in order to obtain crystal 
structures of protein-ligand complexes. In the final step, the best compounds were optimized 
to give more potent inhibitors (Figure 4.15). 
 
 
 
 
 
 
Figure 4.15 The workflow of the study.  
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4.4.1 Library design 

The fragment library suitable for the STD NMR screening was designed and prepared by 
Michael Goldflam in the laboratory of prof. Ernest Giralt (IRB Barcelona). The first and the 
second part of the library together consist of approximately 527 molecules selected from the 
initial set of over 1.2 million compounds and collected from different vendors. The chosen 
compounds were soluble in aqueous solutions, exhibited a molecular weight between 150 and 
300 Da and possessed drug-like properties. The library was composed of structurally and 
chemically diverse molecules that were able to cover chemical space in an optimal manner. 
 
4.4.2. STD NMR-based fragment screening 

Saturation-transfer NMR spectroscopy was introduced in 1999 by Meyer [131, 132] and has 
been used for many years to characterize interaction between protein and ligand in solution 
under physiological conditions. In a typical STD experiment, 1D 1H NMR spectra are 
recorded for a ligand in the presence of a small amount of target, with and without selective 
irradiation of protein. During selective irradiation, the magnetization spreads through the 
protein by intra-molecular cross-relaxation and it is transferred to the bound ligands during its 
residence time in the target [133]. In the case of longer relaxation rates for the hydrogen atoms 
of the small molecule than the dissociation rate constant (koff) of the complex (typically true for 
ligands with μM to mM dissociation constants), there will be an accumulation of the saturated 
ligand (even for the substoichiometric protein concentration). The selective saturation of the 
protein target can be obtained by irradiating the aliphatic region of the 1H NMR (typically 
between -1 and 2 ppm), usually well populated by methyl groups of the protein, but are not 
occupied by resonances from small-molecule, organic ligands. Subsequently, a difference 
spectrum is generated from two spectra that are recorded with and without pre-irradiation 
(Figure 4.16). 
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Figure 4.16 Schematic representation of the STD-NMR experiment. 
 
For large ligands it is possible to predict binding epitope. This is because the molecule that 
interacts directly with the protein, receive the highest degree of saturation which can be 
identified as a stronger STD signal [24, 134]. 
The fragment library contained initially 402 molecules, and was further expanded with 
additional 125 fragments reaching finally 527 compounds. Both parts of the library were 
screened separately following the same steps. In the first step, the compounds that bound to 
EV-B93 3C protease were identified on the basis of the visible STD signals. At this point all 
the fragments that interact with all binding sites of the protein were selected (Figure 4.17, top). 
The experiment was repeated for all positive hits to confirm their binding to EV-B93 3C 
protease. Subsequently, the positive hits were taken to perform the competitive STD NMR 
screening in the presence of irreversible covalent binder rupintrivir. Rupintrivir was chosen due 
to its excellent affinity to EV-B93 3C protease as well as ability to occupy completely the 
proteolytic active site. During this step, only molecules that interact with the enzyme (outside 
of proteolytic active pocket) showed the STD signals, and were therefore excluded from further 
studies. The compounds that possess affinity to the proteolytic active side could not compete 
with rupintrivir, therefore did not bind to EV-B93 3C protease (Figure 4.17, bottom). No 
STD signals were recorded for these molecules. 
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Figure 4.17 Schematic representation of the STD NMR fragment screening and the STD NMR 
competitive screening. Navy blue shape represents EV-B93 3C protease; blue, yellow, green and violet 
shapes correspond to the low-molecular compounds coming from the fragment library and pink shape 
represents covalent inhibitor rupintrivir. 
 
The screening of the first part of the library (402 compounds) resulted in the selection of 38 
molecules that interacted with EV-B93 3C protease, among which 24 gave strong STD signals. 
When repeating the experiment in the presence of rupintrivir, 11 compounds showed good 
competition (no STD signal was observed), 9 average competition (reduced STD signals were 
observed) and 4 no competition (STD signals did not change their intensity). In the case of the 
second part of the library (125 compounds) 13 molecules showed good STD signal with good 
competition in the presence of rupintrivir. The overall hit rate for both primary and 
competitive screening of EV-B93 3C was 4.6 %, since only 24 out of 527 molecules appeared 
to interact relatively strongly with the protease active site. 
The aim of the screening process was to identify the molecules that not only bind to EV-B93 
3C protease but more specifically interact with its proteolytic active site. Various limitations 
should be considered when analyzing the screening data. Firstly, the STD NMR technique is 
able to detect only low or medium binding affinities. Compounds with high affinity may not 

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be detected showing false negative results. However, this kind of molecules should not be 
present in the library due to the small size of the fragments. The second problem is related to 
the false positives that can arise by two means: by direct irradiation of ligand signals or by the 
presence of aggregates. Irradiation of the ligand may occur when the frequency of the 
saturation pulse is set too close to the aliphatic signals of the molecule. Thus, one should be 
very careful not to confuse those spectra. Repeating the spectrum in the absence of the protein 
may help to identify the presence of the aggregates. If the STD signals are still observed, they 
originate from ligand aggregates. 
The overall hit rate for EV-B93 3C protease was 4.6 % which is in accordance with the hit 
rates for fragment based screening mentioned in the literature. The reported hit rates vary from 
0.01 to 0.94 % for multiple screening campaigns [135] to 10 % for FABP4 [136]. The 
extreme example was described for norovirus-like particle where the observed hit rate reached 
61 %, possibly due to the size of the target [137]. 
Small, simple molecules have lower affinities than HTS compounds, but when screened at high 
concentration, they result in higher hit rate, which is a good indicator for a protein 
druggability [135]. The fragment screening of EV-B93 3C protease gave quite low hit rate 
which may suggest poor druggability of the protein. Indeed, the crystal structure described in 
the section 4.1.4 revealed no deeply embedded cavity, but rather shallow binding pocket 
widely dispersed over the protein surface.  
 
4.4.3 Biophysical validation of the selected hits – TSA 
 
The ligand-induced thermodynamic stabilization method commonly known as thermofluor or 
thermal shift assay was introduced by 3DP (currently part of Johnson&Johnson) [138, 139]. 
In this technique, the stabilization manifests as an increase in thermal stability upon binding of 
a ligand. The experiment is performed with a real time PCR machine (qPCR) and 
environmentally sensitive fluorescent dyes such as 1,8-ANS, 2,6-TNS or Sypro Orange, which 
bind to hydrophobic regions exposed on the protein during unfolding process. The 
fluorescence is quenched in an aqueous solution, but starts to be visible in the hydrophobic 
environment. Fluorescence increases gradually when more hydrophobic residues of the protein 
become exposed during heating process and this way melting curve can be recorded. Melting 
temperature, Tm, is defined as the temperature at which 50 % of the protein is unfolded. 
Comparison of this value with melting temperature of the protein in an absence of a ligand, 
T0, allows the determination of the degree of stabilization. Using this method, the validation of 
38 hits coming from the screening of the first part of the library was done. High concentration 
of each compound (1 mM) was used due to expected low affinities of the selected fragments to 
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EV-B93 3C protease. The melting curve raw data were plotted as fluorescence versus 
temperature (Figure 4.18 A). In order to visualize the Tm more clearly, the negative first 
derivatives were plotted, making the Tms appear as peaks (Figure 4.18 B). No significant 
thermal shifts were observed for any of the tested compounds. The protein alone showed 
melting temperature equal to 54.5 °C, while in the presence of 38 hits the Tm values ranged 
from 54.5 to 55.0 °C, which fell within the measurement error. Due to weak response of EV-
B93 3C protease in the thermal shift assay, the most promising hits from the second part of the 
library were not evaluated by this method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Melting curves for EV-B93 3C protease alone and in the presence of 8 random hits from 
the first part of the screening. The fluorescence response (relative fluorescence units, RFU) versus time 
(A) and the negative first derivative of the change in fluorescence versus time (B). 
 
Thermal shift assay is not as sensitive as STD NMR, thus may not be able to detect weak 
affinities. On the other hand, the fragments themselves may not stabilize the protein enough to 
change its melting temperature, which can result in many false negatives during fragment 
screening or hit validation. Both aforementioned statements are probably true for EV-B93 3C 
protease, since none of the hits showed stronger (Tm-T0 > 0.5 °C) stabilization of the protein. 
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However, there may be the third cause of an inability for further stabilization of the protein – 
the high melting temperature value. Indeed, EV-B93 3C protease has relatively high melting 
temperature equal to 54.5 °C. It was described in the literature that thermostability of proteins 
depends on many factors among which are: surface contribution of polar atoms (nitrogen and 
oxygen atoms) able to form hydrogen bonding with water molecules, better hydrophobic 
internal packing, protein density and volume of the cavities present in the protein [140]. It was 
already mentioned that EV-B93 3C protease is a very compact enzyme lacking deep cavities. 
Moreover, it is very soluble in aqueous solutions due to the presence of a polar surface and 
a deeply hidden hydrophobic core. The above suggestion was proven in the thermal shift assay 
performed in the presence of rupintrivir, potent inhibitor of EV-B93 3C protease, which 
served as a positive control. Rupintrivir was also unable to further stabilize the protein. 
 
Thermofluor was not the best method for the hit validation in the case of EV-B93 3C protease, 
however, its performance varies for different protein targets [141]. For example, thermal shift 
assay was proven to be the most appropriate fragment screening method for the tumor 
suppressor p53, which reactivates upon binding of small organic molecules due to thermal 
stabilization [142]. 
 
4.4.4 Biophysical validation of the selected hits – SPR 
 
Surface plasmon resonance (SPR) technology has emerged as a powerful technique to 
investigate the interaction between low-molecular-weight molecules and target proteins. The 
first commercial Biacore instrument was developed by Pharmacia Biosensor in 1990 [143]. 
SPR occurs when plane-polarized light hits a metal film (usually silver or gold) under 
conditions of total internal reflection. The SPR angle, which is the angle of the incident light 
that results in the lowest intensity of reflected light at a constant wavelength, depends mainly 
on the properties of the metal film and the refractive index of the medium that is close to that 
film. By monitoring alterations in the refractive index, SPR is able to measure changes in the 
mass of dissolved material in the aqueous layer close to the metal film which allows the 
interaction of proteins with other molecules or ligands to be monitored in real-time [144]. 
This allows for determination of the kinetic parameters and equilibrium constants, i.e. on-rate, 
off-rate, dissociation constants as well as thermodynamic parameters. The signal of SPR 
depends linearly on the mass of binding ligand to the immobilized target. The resulting 
sensogram includes association and dissociation phase (Figure 4.19). 
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Figure 4.19 Experimental set up of SPR and a sensogram. 
 
51 compounds coming from the STD NMR screening were tested in SPR to order the hits 
according to their Kd values. The first trial was done using amine coupling for the 
immobilization of EV-B93 3C protease via its free primary amine groups (lysine residues). 
Regrettably, the maximum binding response Rmax for the screened molecules was very low 
around 5 RU while the expected values should oscillate between 15-26 RU (response unit). 
This may have occurred due to the random orientations of the bounded protein and the lack of 
homogeneity, which could result in the partial blockage of the protein active site. To overcome 
this problem indirect capture immobilization was applied. This method involves high-affinity 
capture of His-tagged protein onto covalently immobilized anti-His antibodies. The benefit of 
this capture approach is the creation of a homogenous surface, since all protein molecules are 
orientated through a common site – His-tag. This time the obtained results seemed to be 
reasonable and repeatable (Table 4.9). 
 
Table 4.9 Results of validation by SPR 
no. name molecular mass [Da] Kd [M] 
1 92 241 522.4 
2 144 192 nd 
3 160 178 113.4 
4 164 210 270.9 
5 168 216 167.7 
6 169 256 297.2 
7 179 174 135.2 
8 188 233 297.8 
9 211 222 23.0 
10 227 203 nd 
11 232 172 150.7 
12 239 169 298.3 
13 241 217 12.1 
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14 243 202 89.1 
15 259 157 91.1 
16 290 190 243.2 
17 306 292 168.2 
18 307 230 168.2 
19 318 174 363.6 
20 404 159 279.0 
21 406 150 141.3 
22 412 164 290.2 
23 427 173 275.6 
24 432 195 352.8 
25 438 193 1096.0 
26 441 157 163.4 
27 442 186 263.6 
28 443 166 272.3 
29 445 213 477.4 
30 459 178 90.6 
31 471 215 263.1 
32 476 267 89.0 
33 484 162 293.3 
34 487 271 219.9 
35 494 178 220.4 
36 542 176 237.9 
37 544 193 177.3 
38 550 179 252.1 
39 578 193 261.5 
40 606 232 253.0 
41 629 218 185.0 
42 631 197 252.0 
43 635 215 366.3 
44 644 279 836.5 
45 656 248 353.3 
46 668 207 nd 
47 675 246 51.2 
48 686 227 146.9 
49 688 233 1544.0 
50 717 271 nd 
51 723 210 135.0 
nd – not determined; compounds and corresponding Kd values < 100 μM 
are indicated in bold blue; compounds and corresponding Kd value ≈ 100 
μM are indicated in blue 
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 The affinity determination (Kd) of the fragments was assessed on the basis of the binding 
isotherm obtained by the screening of 5 different concentrations of a ligand (0, 0.125, 0.250, 
0.5 and 1 mM). The estimation of the kinetic constants was impossible due to the fast kinetics 
of the fragments. 6 compounds showed Kd lower or very close to 100 μM (Table 4.10). In 
three cases the Kd was impossible to be measured because of the solubility problem or 
insufficient amount of compound, which left after the TSA. 
 
Table 4.10 Chemical structures of the most potent hits in the SPR 
experiment. 
name Kd [μM] chemical structure 
241 12.1 
 
 
 
 
211 23.0 




 
675 51.2 




 
 
 
476 89.0 




 
 
459 90.6 




 
160 113.4 




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The analysis of the selected fragment hits showed a number of structural similarities. All the 
compounds have at least one aromatic or heteroaromatic ring. 4 out of 6 molecules possess two 
aromatic (one five-member and one six-member) rings separated by the different-length spacers 
(only covalent bond for compound 241 and 160, the one-atom spacer for compound 211 and 
the two-atom spacer for compound 476). 3 fragments have the 4-methylphenyl moiety (241, 
211 and 459) while one possesses the 4-metoxyphenyl (476) residue. 5 molecules have the 
heterocyclic ring with one (675, 160), two (211, 476) or three nitrogen atoms (241). 
 
4.4.5 In vitro  proteolytic assay 
6 most promising compounds with the highest affinity were characterized in the in vitro 
proteolytic assay with EV-B93 3C protease. Only one compound 241 with the best Kd value 
showed inhibitory effect (RA-relative activity = 76 %) at high concentration 350 μM (protein 
compound ratio: 1:200) (Figure 4.20). Thus, the compound 241 was chosen for further 
elaboration. 
          
Figure 4.20 In vitro proteolytic activity assay of EV-B93 3C protease in the absence and presence of the 
small molecule 241 at high concentration 350 μM.  
 

Results and discussion 

 
103
4.4.6 Elaboration of compound 241 

44 analogs of the best hit 241 were selected based on the sub-structural similarity searching 
(done by Daniel Álvarez from prof. Xavier Barril’s laboratory, the University of Barcelona), and 
purchased from different vendors. All the compounds were tested in the in vitro proteolytic 
assay at high concentration 350 μM (protein compound ratio: 1:200). The chemical structures 
of compounds and their inhibitory activities are listed in Table 4.11. 
 
Table 4.11 Analogs of compound 241 and their inhibitory activity against EV-
B93 3C protease. 
no. name 
molecul
ar mass 
[Da] 
chemical structure RA
i 
[%] 
1 EN1 175 
 
5.5ii 
2 EN2 189 
 
0.0 
3 EN3 202 
 
100 
4 EN4 226 
 
100 
5 EN5 242 
 
100 
6 EN6 244 
 
100 
7 EN7 259 
 
100 
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8 EN8 260 
 
98.6 
9 EN9 269 
 
3.0 
10 EN10 269 
 
64.7ii
i  
11 EN11 274 
 
98.3 
12 EN12 279 
 
0.0 
13 EN13 279 
 
99.7 
14 EN14 283 
 
93.6 
15 EN15 287 
 
100 
16 EN16 249 
 
51.4 
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17 EN17 299 
 
80.3 
18 EN18 310 
 
84.6 
19 EN19 324 
 
82 
20 EN20 359 
 
53.3 
21 D1 411 
 
76.7 
22 D2 285 
 
54.0 
23 D3 396 
 
65.8 
 

Results and discussion 

 
106
24 D4 315 
 
94.1 
25 D5 279 
 
0.0 
26 D6 301 
 
82.7 
27 D7 348 
 
68.3 
28 D8 324 
 
96.5 
29 D9 329 
 
38.6 
30 D10 295 
 
87.2 
31 D12 254 
 
72.5 
32 D13 189 
 
92.7 
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33 D14 300 
 
74.6 
34 D15 188 
 
67.5 
35 D16 208 
 
76.1 
36 D17 189 
 
0.0 
37 A1 362 
 
50.0 
38 A2 268 
 
98.4 
39 A3 288 
 
96.6 
40 A4 379 
 
0.0 
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41 A5 304 
 
65.7 
42 A6 281 
 
73.5 
43 A7 206 
 
82.1 
44 FCH 255 
 
69.0 
iRA – relative activity of EV-B93 3C protease; the molecules for which RA < 6 % are highlighted in 
red; the molecules for which 30 % < RA < 70% are highlighted in blue. 
 
7 compounds out of 44 were able to inhibit EV-B93 3C protease effectively (RA < 6 %) 
(Figure 4.21 A). For those compounds, the IC50 values were estimated based on the 
corresponding dose-response curves (Figure 4.21 B). The values ranged from 115 μM for the 
compound D17 to 5 μM for the compound A4. The best 4 molecules: A4, EN2, EN12 and 
D17 were taken for further evaluation. 
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Figure 4.21 Relative activity of EV-B93 3C protease in the presence of 44 analogs of compound 241 at 
high concentration (350 μM) (A). The IC50s for 7 best compounds were estimated based on the 
corresponding dose-response curves (B). 
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Next, structure-activity relationship (SAR) of 44 analogs was analyzed in order to improve the 
potency of the most promising compounds. Several observations supported by the additional 
experiments have been made and are as follows: 
1. The triazole ring B is necessary for the activity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 SAR comparison of the selected compounds based on the presence of the triazole ring B. 
Relative activity (RA) is shown for each compound. IC50 values are shown for the compounds EN2 
and D17. 
  
In the case of compounds with 2 (A and B) or 3 (A, B and C) rings, the triazole ring B is 
essential for their potency (Figure 4.22, compounds EN2 and EN12). Any changes in the 
order of the nitrogen atoms (compound D17) or reduction of their number resulted in the 
activity loss (compounds D15 and D13). For the molecules with 4 rings this tendency is not so 
evident (compound A4 in Figure 4.26).  
2. For the compounds bearing two aromatic rings (A and B) and in some cases even three 
aromatic rings (A, B and C) the presence of the methyl group in the triazole ring B causes a 
considerable activity loss (Figure 4.23).  
EN2-RA 0 % 
IC50 ≈ 16 μM 
D17-RA 0 % 
IC50 ≈ 37 μM 
D13-RA 93 % 
D15-RA 68 % 
EN12-RA 0 % 
A6-RA 74 % 
D10-RA 87 % 
D2-RA 54 % 
A3-RA 97 % 
A B 
C 
A B 
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3. The presence of the methyl group in the para position of the phenyl ring A affects the 
inhibitory activity in the case of the molecules with two aromatic rings A and B (Figure 4.23). 
 
 
 
 
 
 
 
 
 
Figure 4.23 SAR comparison of the selected compounds based on the presence of the methyl groups in 
the ring A and B. Relative activity (RA) is shown for each compound.  
 
The statement 2 is generally true for the 2- or 3-ring molecules, while the statement 3 was 
supported by the additional experiments performed with the compounds with 2 aromatic rings 
DB1 and DB6 (synthesized by Daniel Becker from the Freie Universität in Berlin). The 
compound 241 selected in the STD NMR screening is a weak inhibitor of EV-B93 3C 
protease (RA ≈ 76 %). The elimination of only one methyl group (from the triazole ring B) did 
not change its potency (Figure 4.23, compound DB1 with RA ≈ 80 %). However, the removal 
of the second methyl group (from the phenyl ring A) resulted in the substantial increase in the 
potency (compound EN2 with RA ≈ 0 %). The same observation was made for the 
compounds DB6 and EN1. Deleting both methyl groups from the ring A and B of the 
compound DB6 (RA ≈ 100 %) gave the molecule EN 1 with a good inhibitory activity (RA ≈
6 %). The presence of only one methyl group in the 3-ring compound EN14 was not favorable 
for its activity (RA ≈ 94 %), since its elimination resulted in the potent inhibitor EN9 (RA ≈ 3 
%). Not enough data were gathered to support the same hypothesis for the 4-ring analogs.  
 
 
 
A B 
241-RA 76 % 
EN2-RA 0 % EN9-RA 3 % 
EN14-RA 94 % 
DB1: RA 80 % 
DB6-RA 100 % 
EN1-RA 6 % 
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4. The aliphatic substitutions in the triazole ring B lead to the activity loss. 
 
 
 
 
 
 
 
Figure 4.24 SAR comparison of the selected compounds based on the presence of the aliphatic 
substitutions in the ring B. Relative activity (RA) is shown for each compound.  
When the amide moiety in the position of the ring C contains an aliphatic group, the 
compound loses completely its activity (Figure 4.24). 
 
 
 
 
 
 
 
 
 
 

EN8-RA 99 % EN3-RA 100 % 


EN4-RA 100 % 
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5. The additional third aromatic ring C with appropriate heteroatoms and groups enhances the 
potency of the compound. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25 SAR comparison of the selected compounds based on the presence of the ring C with 
appropriate heteroatoms. Relative activity (RA) and IC50 values are shown for each compound.  
 
The most active molecules with 3 aromatic rings contains one nitrogen atom in para position 
of the ring C and preferably no larger than methyl substituents (Figure 4.25, compounds EN9 
and EN12). The amide bond should be linked with the ring C by a covalent bond. Any 
additional atoms in a linker lead to the decrease of the activity (compound D5). 
 
 
 
 
 
 
 
EN9-RA 4 % 
IC50≈85 μM 
EN12-RA 0 % 
IC50≈33 μM 
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6. The number and position of the nitrogen atoms in the ring C affect the inhibitory activity. 
The ortho position for the nitrogen atom is favorable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 SAR comparison of the selected compounds based on the presence and number of the 
nitrogen atoms in the ring C. Relative activity (RA) is shown for each compound. IC50 values are 
shown for the compounds EN9, EN12 and D5. 
 
One nitrogen atom in the ortho position of the ring C seems to be optimal for the good 
inhibitory activity of a compound (Figure 4.26, compounds EN12, D5 and EN9). Any 
additional heteroatoms cause the decrease in the activity. 
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7. The additional forth aromatic ring D can have some positive effect on the inhibitory 
activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 SAR comparison of the selected compounds based on the presence of the aromatic ring D. 
Relative activity (RA) is shown for each compound. 
 
The introduction of the ring D may lead to a potent inhibitor (Figure 4.27, compound A4). 
The compound bearing the ring D is less sensitive to other unfavorable substitutions, i.e. 
methyl in the triazole ring B (compound EN20) or in the phenyl ring A (compound A4), 
additional heteroatoms in the ring C (compounds EN20, D7, A1, D3 and A4) or even lack of 
the triazole ring B (compound A4). 
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4.4.7 Chemical optimization of the best compound A4 
 
Among all purchased analogs, the compound A4 showed the best inhibitory activity against EV 
B93-3C protease with the IC50 ≈ 5 μM (protein inhibitor ratio 1:2.6). The molecule obeys a 
couple of rules listed in section 4.1.6 and can be used as a starting point for further 
modification in order to improve its potency. The compound A4 possesses 4 aromatic rings 
and does not have a methyl group in the ring B. Moreover, its ring C has a nitrogen atom in 
the ortho position. However, there are some unfavorable features that may be modified to 
improve the potency of the A4 analogs. The compound lacks the presence of the triazole 
group, which is substituted by the thiazole ring. Additionally, the phenyl ring A has a methyl 
group in the para position (Figure 4.28). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28 Compound A4 as an inhibitor. Chemical features that may affect the inhibitory properties 
are marked in blue. 
 
Two analogs of the compound A4 were proposed (A4_B and A4_C) in order to improve its 
inhibitory activity against EV-B93 3C protease. Both compounds have the triazole ring B. The 
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compound A4_B kept the methyl group in the para position of the phenyl ring A, while this 
substitution was removed in the case of the compound A4_C (Figure 4.29 A). The chemical 
synthesis was done by Daniel Becker from the Freie Universität in Berlin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 Chemical structures of two analogs of A4: A4_B and A4_C (A). Comparison of the activity 
of EV-B93 3C protease in the presence of different concentrations of A4, A4_B and A4_C (B). 
 
The inhibitory potency of A4_B and A4_C towards EV-B93 3C protease was verified in the in 
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considerably weaker inhibition against the protein than the molecule A4 (Figure 4.29 B). This 
result suggested that another feature present in the compound A4 is much more important for 
the activity than the triazole ring. The careful structure analysis of A4 and its analogs revealed 
that nitrogen atom in the para position from the ring D must be responsible for the enormous 
inhibitory activity of the A4 molecule. The appropriate analog (A4_D) was commercially 
available (Figure 4.30 A). Activity evaluation proved that the A4_D analog is similarly active 
towards EV-B93 3C protease (IC50 ≈ 5 μM) when compared to A4, but is more efficient 
during inhibition (at 20 μM compound A4_D is able to inactivate the protease almost 
completely while 20 % of the activity is still observed in the case of the molecule A4) (Figure 
4.30 B).  
 
Figure 4.30 Chemical structure of the third analog of A4: A4_D (A). Comparison of the activity of EV-
B93 3C protease in the presence of different concentrations of A4 and A4_D (B). Important nitrogen 
atom is encircled in pink. 
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Looking at the molecule A4_D it is easy to notice that it is structurally symmetric. After the 
cleavage of the peptide bond, it is possible to get two similar compounds with 5 and 6-member 
rings each (Figure 4.31, compounds A and B). Compound A is equivalent to compound EN2, 
while compound B, called PA4, was purchased from a commercial vendor. Both compounds 
were tested in the proteolytic activity assay with EV-B93 3C protease. 
 
 
 
 
 
 
 
 
 
 
Figure 4.31 Peptide bond cleavage in the compound A4_D gives two compounds A (EN2) and B 
(PA4). 
The molecule A showed good inhibitory activity against EV-B93 3C protease. The presence of 
the nitrogen atom in the molecules A4 or A4_D is crucial for their potency, which may suggest 
that the second molecule B alone can be active as well. To prove this hypothesis the compound 
PA4 was purchased and its inhibition towards EV-B93 3C protease was evaluated in the in 
vitro proteolytic assay (Figure 4.32). 
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Figure 4.32 Comparison of the activity of EV-B93 3C protease in the presence of different 
concentrations of A4, EN2 and PA4. 
 
The compound PA4 exhibited considerable good inhibitory activity (IC50 ≈ 29 μM) against 
EV-B93 3C protease, however its potency was not as good as of the compound EN2 or A4. 
This experiment shows that the nitrogen atom in the pyridine ring D is extremely important 
for the activity of the molecule A4/A4_D. The compound PA4 was very active even without 
the triazole ring which is crucial for the activity of the molecules containing only two aromatic 
rings. 
Ligand efficiency (  
 
) can provide a useful comparison between 
compounds with different MWs and the IC50 values, and can be applied for the monitoring of 
the ligand optimization process. In general, the LEs of starting fragments are greater than those 
of larger, more elaborated structures. However, the ligand efficiency values should not decrease 
much and at least stay constant when altering a lead molecule. In the case of the compounds 
EN2 and PA4, the LE values are relatively high (0.34 and 0.38, respectively). The combination 
of these two compounds resulted in the molecule A4_D with the LE equal to 0.21. This 
suggests that the optimization step would be desirable for the improvement of its potency by 
reaching the LE value closer to 0.3. This can be a challenging goal to achieve, since no 
information of the binding mode is known. Using only chemical structures of the compound 
A4 or A4_D it is impossible to predict their binding sides in the active pocket of EV-B93 3C 
protease without further structural or bioinformatics studies (see sections 4.4.8 and 4.4.11). 
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4.4.8 Co-crystall ization/soaking trials 

The co-crystallization as well as soaking trials were performed at the each step of the study. In 
the case of the hits selected in the screening, the co-crystallization trials were done in the 
presence of the 20-fold excess of a compound. For more potent analogs (i.e. A4, EN2, EN12 
and A4_D) the crystallization screening were performed in the 5, 10 or 20-fold excess of a 
ligand. Additionally, for the molecules A4 and A4_D, the crystallization condition was 
performed in the equimolar presence of the peptide substrate, and was followed by the seeding 
with the EV-B93-compound 1 complex crystals. The procedure was aimed at aiding the 
protein to crystallize in the crystal form matching the one obtained for the covalent complexes 
(Figure 4.33 C). The soaking of the EV-B93 3C protease crystals was done with all promising 
ligands but was not always possible to fish the crystal due to its dissolution or heavy 
precipitation of a soaking compound. The diffraction of more than 200 crystals led to more 
than 100 datasets that unfortunately did not show any additional electron density in the active 
site that could be unambiguously assigned to any of the ligands.
 
 
 
 
 
 
Figure 4.33 Different crystals obtained during crystallization trials with non-covalent ligands. EV-B93 
3C protease crystals: native (A), methylated (B) and after seeding with EV-B93-compound 1 complex 
crystals (C). 
 
In order to change the physicochemical properties of the protein and enhance the formation of 
the protein-ligand complex, EV-B93 3C protease was methylated. This method was 
successfully applied to obtain only one known crystal structure of the non-covalent protein-
ligand complex with HRV 3C protease [114]. However, the result was not reproducible even 
by the authors of the paper. EV-B93 3C protease was subjected to a reductive methylation. 
According to the MALDI-TOF spectra the protein was modified by 24 methyl groups (the 
mass changed from 21379 Da to 21715 Da), which may attach not only to the lysine side 
chains, but also to the N-terminal end and the cysteine active site. The methylation of the 
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cysteine was supposed to be removed by the incubation with DTT, but it was not successful in 
the case of EV-B93 3C protease, since the modified protein showed no activity in the in vitro 
proteolytic assay. The crystallization screening of the methylated protein resulted in several, but 
much less crystallization conditions containing the small needle-like crystals when compared to 
native EV-B93 3C protease (Figure 4.34 B). The optimization process was much more difficult 
and did not yield any high quality crystals appropriate for soaking trials. Only one crystal was 
suitable for X-ray diffraction, but it did not reveal any additional electron density in the 
proteolytic active site.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34 MALDI-TOF spectra of native EV-B93 3C protease (A) and after reductive methylation 
(B). 
 
The inability of obtaining the stable protein-non-covalent ligand complex with EV-B93 3C 
protease was possibly due to the nature of the specificity pockets for the substrate (or inhibitor) 
recognition. The active sites of the serine and cysteine proteases are usually shallow, and the 
binding determinants are widely dispersed over large surface areas. In this situation the 
bounded molecule interacts only partially with the protein, and possesses a few effective 
residues exposed to the solvent. The situation is opposite in the case of deep and narrow active 
sites where substrates/inhibitors are able to interact more efficiently with the protein, thus 
being easier to obtain protein-ligand complex structures. In this case, even for low-molecular 
mass [m/z] 
in
te
ns
ity
 [%
] 
in
te
ns
ity
 [%
] 
mass [m/z] 
A 
21379 Da 21715 Da 
B 
 

Results and discussion 

 
123
weight compounds it is possible to get high-affinity complexes with a target protein. The 
situation is much less favourable for molecules interacting with widely solvent-exposed active 
sites of serine and cysteine proteases, where a ligand occupancy value is reduced, which results 
in low or none electron density. 
Another possible explanation of the inability to determine the non-covalent EV-B93 3C 
protease-ligand complex structure is that interactions between the protein molecules in the 
crystal could be stronger than between the protein and a small compound. Thus, 
conformational changes necessary for the ligand binding cannot occur and the protein 
crystallizes alone. The same situation may occur during soaking experiments. The already 
formed protein-protein interactions in the crystal can be too strong to be disrupted upon 
binding of a low molecular weight molecule. A non-favorable conformation of the protein in 
the crystal state may not allow the compound to form stable non-covalent interaction with the 
active site. The situation is opposite with covalent inhibitors, which are bounded strongly 
enough to the protein and are able to alter its conformation. 
Finally, the non-covalently bound ligands may exhibit greater thermal motion or 
conformational disorder than the surrounding protein, leading to a poor and insufficient 
electron density, preventing the identification of a molecule in the active site of an enzyme. 
 
4.4.9 Homologous 3C proteases as targets for the best compounds  
 
Due to the good inhibitory activity of the compounds A4, EN2, EN12 and D17 against EV-
B93 3C protease in the in vitro proteolytic assay, their potency was also tested towards the 
homologous picornaviral 3C proteases from HRV-A49, EV-D68, AiV, PSV and ERBV-1 
(Table 4.11).  
 
Table 4.11 Picornaviral 3C proteases tested with the best analogs of 
compound 241 
Genus Species Serotype 
Enterovirus Rhinovirus A HRV-A49 
Enterovirus Enterovirus D EV-D68 
Kobuvirus Aichivirus A AiV 
Sapelovirus Porcine sapelovirus PSV 
Erbovirus Equine rhinitis B virus ERBV-1 
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In the first step, the proteolytic activity of the homologous proteins was compared in the 
biochemical assay. 3C proteases from HRV-A49, EV-D68, AiV and PSV were able to cleave 
the peptide containing the Q↓G sequence, while ERBV-1 3C protease processed the same 
peptide with a very low yield < 5 %. For this protein a new peptide was ordered with the Q↓S 
sequence that mimics 2C/3A and 3A/3B cleavage site in the polyprotein of ERBV-1. The 
differences in the cleavage efficiency were observed. The most effective proteins appeared to be 
HRV-A49 and EV-D68 3C proteases, which processed the peptide completely during 3 h in 
37 °C. In the case of the protease from PSV the cleavage progress was a little bit smaller (96 
%), while for AiV and ERBV-1 3C proteases the cleavage efficiency was similar to those 
observed for EV-B93 3C protease and corresponds to 60 % (Figure 4.35). 
 
 
Figure 4.35 Cleavage efficiencies of 6 tested 3C proteases from HRV-A49, EV-D68, AiV, PSV, ERBV-
1 and EV-B93 observed after 3 h-incubation at 37 °C. Blue and navy blue bars corresponding to 
peptides with the Q↓G and the Q↓S cleavage site, respectively. 
In the in vitro assay all the compounds demonstrated inhibitory activity against homologous 
proteases. The potency of the analogs A4, EN2, EN12 and D17 was decreasing in the same 
order as for EV-B93 3C protease, i.e. the best compound was A4, and then EN2, EN12 and 
the least potent was D17 (Figure 4.36). The highest activity of the molecules was observed 
against AiV, PSV and ERBV-1 3C proteases and was similar for EV-B93 3C protease. HRV-
A49 and EV-D68 3C proteases appeared to be much worse targets for A4, EN2, EN12 and 
D17. A4 demonstrated the best potency with IC50: 4, 8 and 5 μM for AiV, PSV and ERBV-1 
3C protease, respectively. All the IC50 values are gathered in Table 4.12.  
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Figure 4.36 Relative activity of the homologous 3C proteases from HRV-A49 (A), EV-D68 (B), AiV 
(C), PSV (D), ERBV-1 (E) and EV-B93 (F) in the presence of different concentrations of A4, EN2, 
EN12 and D17. 
 
Table 4.12 IC50 values [μM] of A4, EN2, EN12 and D17 for HRV-A49, EV-
D68, AiV, ERBV-1 and EV-B93 3C proteases estimated on the corresponding 
dose-response curves (Figure 4.33) 
 HRV-
A49 
EV-D68 AiV PSV ERBV-1 EV-B93 
A4 16 39 4 8 5 5 
EN2 35 45 7 13 9 16 
EN12 86 41 16 17 20 33 
D17 140 173 27 20 20 37 
 
Since the compound A4 was the most potent towards homologous 3C proteases, the analogs of 
A4 (A4_B, A4_C and A4_D) were also tested. Firstly, due to the possible weak potency of 
A4_B and A4_C, the activity of the molecules was determined at one, high concentration of 
350 μM (Figure 4.37). At this concentration, the inhibition of the potent compounds should 
reach 100 % (relative activity (RA) of the protease should be 0 %). 
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Figure 4.37 Comparison of the inhibitory activity of A4 and its analogs A4_B, A4_C and A4_D at 350 
μM concentration towards 3C proteases from HRV-A49, EV-D68, AiV, PSV, ERBV-1 and EV-B93. 
 
The analogs A4_B and A4_C were the weakest inhibitors towards homologous 3C proteases 
and the results were similar to those observed for EV-B93 3C protease. For all tested proteins 
the molecule A4_C was slightly worse than A4_B. This proves that for the inhibitors 
containing 4 aromatic rings, the methyl group in the phenyl ring A is favorable for the activity, 
which is opposite for the compounds with 3 or 2 aromatic rings. Only in the case of ERBV-1 
3C protease, the molecule A4_B was able to inhibit completely the protein activity at 350 μM. 
The compound A4_D demonstrated a very good inhibitory activity, since it inhibited almost 
all proteases (for 3C protease from EV-D68 the relative activity was very low 2.6 %). In order 
to estimate the IC50 values for A4_D in the presence of the homologous 3C proteases, dose-
response curves were plotted. The values were compared with those obtained for the 
compound A4 (Figure 4.35 A, B, C, D, E). The same curve was prepared for the compound 
A4_B and ERBV-1 3C protease (Figure 4.38 F). 
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Figure 4.38 Dose-response curves of A4 and A4_D against homologous 3C proteases from HRV-A49 
(A), EV-D68 (B), AiV (C), PSV (D) and ERBV-1 (E). Dose-response curve of A4_B against ERBV-1 
3C protease (F). 
 
The compounds A4 and A4_D showed the same or similar activity towards 3C proteases from 
AiV, PSV and ERBV-1. However, in the case of the proteins against which the compounds A4 
and A4_D had poor inhibitory performance, the differences in the potency were more 
noticeable. For HRV-A49 3C protease, the analog A4_D appeared to be weaker inhibitor than 
A4 (IC50s were ca. 37 μM vs. 16 μM, respectively). The opposite effect was found for EV-
D68 3C protease, where molecule A4_D showed better potency than A4 (IC50s were ca. 19 
μM vs. 39 μM, respectively). The compound A4_B was very active against ERBV-1 3C 
protease at 350 μM, but was not able to reduce the activity of the protein by 50 % at the 
concentration lower than 100 μM.  
 
EV-B93, EV-A49, EV-D68, AiV, PSV and ERBV-1 belong to a different picornaviral genus. 
EV-B93, EV-A49, EV-D68 are part of the Enterovirus genus, while AiV, PSV and ERBV-1 are 
classified within the Kobuvirus, Sapelovirus and Erbovirus genus, respectively. Multiple 
sequence alignment of the 3C proteases from these viruses revealed that EV-B93 3C protease 
shares the highest sequence similarity with EV-D68, PSV and EV-A49 3C proteases (66.67 %, 
52.46 % and 48.63 %, respectively). However, when comparing to AiV and ERBV-1 3C 
proteases, the sequence identity is very low (14.75 % and 10.93 % respectively) (Table 4.12). 
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Table 4.12 Sequence similarity of 3C proteases from EV-B93, EV-A49, EV-
D68, AiV, PSV and ERBV-1. 
 EV-B93 EV-A49 EV-D68 AiV PSV ERBV 
EV-B93 - 48.63 % 66.67 % 14.75 % 52.46 % 10.93 % 
EV-A49 48.63 % - 48.63 % 19.67 % 45.36 % 13.66 % 
EV-D68 66.67 % 48.63 % - 13.66 % 46.45 % 19.13 % 
AiV 14.75 % 19.67 % 13.66 % - 18.03 % 13.61 % 
PSV 52.46 % 45.36 % 46.45 % 18.03 % - 17.49 % 
ERBV 10.93 % 13.66 % 19.13 % 13.61 % 17.49 % - 
 
Multiple sequence alignment was performed separately between EV-B93 3C protease and more 
similar 3C proteases from EV-A49, EV-D68 and PSV, and between EV-B93 3C protease and 
more distant AiV and ERBV 3C proteases (Figure 4.39 A and B, respectively). In the case of 
the first alignment, most of the residues present in the proteolytic active pocket are conserved. 
For the second alignment the sequence similarity was much less noticeable. Only a few amino 
acids were identical or physico-chemically similar, including one residue from the catalytic 
triad. The Glu-71 in EV-B93 3C protease corresponds to Asp-90 in 3C protease from ERBV-
1. However, the majority of the invariant residues form the proteolytic active site. 
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Figure 4.39 Multiple sequence alignment of 3C proteases from EV-B93, EV-A45, EV-D68 and PSV 
(A) and from EV-B93, AiV and ERBV-1 (B). Invariant residues are white with red background; 
conserved residues are shown in red font. The residues of proteolytic binding site are marked below as 
green bars. Catalytic residues Cys-147, His-40 and Glu-71/Asp-90 are indicated by green asterisks. 
 
Despite the high degree of the sequence similarity among the enteroviral 3C proteases, the 
inhibitory activities of the compounds discovered within this study were very different. For 
instance the molecule A4 exhibited the IC50 ranging from 5 μM for EV-B93 3C protease to 
16 and 39 μM for EV-A49 and EV-D68 3C proteases, respectively. In the case of the non-
enteroviral 3C proteases, the active molecules (A4, EN2, EN12 and D17) displayed higher 
potency with the IC50s close or better to the ones obtained for EV-B93 3C protease (see the 
values in Table 4.12). The observed differences may be related not only to the affinity of a 
compound to the proteolytic active site but also to the peptide substrate specificity. 3C 
proteases from EV-A49 and EV-D68 were able to process the peptide substrate completely 
during 3 h in 37 °C, which did not occur for other homologous proteins including EV-B93 3C 
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protease (Figure 4.35). Moreover, it is worth mentioning that the cleavage specificity of ERBV-
1 3C protease is different from the other tested enzymes, since it recognizes the Q↓S, not the 
Q↓G sequence. This may influence the affinity of its possible inhibitors, for example the 
analog of A4 – A4_B was able to reduce the proteolytic activity of ERBV-1 3C protease 
entirely at 350 μM, while for the homologous 3C proteases only some activity was observed 
(see Figure 4.36). 
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4.4.10 Cell-based assays with the best compounds 

Fragment screening and optimization of the best hit resulted in the potent non-covalent 
inhibitors that displayed good inhibitory activity against isolated 3C proteases not only from 
EV-B93 but also from the homologous picornaviral 3C proteases. Performing cell-based assays 
were aimed at investigating whether the inhibitors are able to enter the cells, are stable in the 
cytoplasmic environment, can inhibit the 3C protease in this condition, or if they are toxic to 
cells. Two different assays were applied in parallel: the cell-based proteolytic assay and the 
antiviral assay. 
 
4.4.10.1 Cell-based proteolytic assay with the best compounds 

The first method allows the verification if the compounds are able to inhibit 3C proteases from 
CV-B3 or EV-A71 in living cells. The assay, developed by our collaborators from the Utrecht 
University in The Netherlands, is based on the induction of expression of a firefly luciferase 
reporter by a chimeric transcription factor [123]. The transcription factor consists of a part of 
the CV-B3 or EV-A71 polyprotein (15 C-terminal amino acids of 3A, 3B, 3Cpro, and 15 N-
terminal acids of 3D) flanked by GAL4 binding domain (GAL4BD) and VP16 activation 
domain (VP16AD). Active protease cleaves the chimeric protein at the 3C protease cleavage 
sites (arrows). If the protease is catalytically inactive, binding of GAL4BD to the GAL4 
sequences in the reporter plasmid recruits VP16AD to the transcription start site, resulting in 
induction of Firefly luciferase expression (Figure 4.40). The use of the inhibitor SG85 or CA 
(Cys147A mutant of CV-B3) served as a positive control, while native protease without any 
addition of the inhibitor served as a negative control. 
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Figure 4.40 Schematic representation of the cell-based proteolytic assay (adapted from [123]). 
 
 All the compounds EN2, EN12, D17, A4 and its analogs A4_B, A4_C and A4_D were tested 
in the cell-based proteolytic assay. For the analogs EN2, EN12 and A4 the maximum 
concentration applied was 200 μM, for the compound D17 it was 2 mM, while for the 
compounds A4_B, A4_C and A4_D the highest concentration tested was equal to 30 μM. 
These values depended on the solubility or cytotoxicity of the compounds (see section 
4.4.10.2). The inhibitory activity was checked towards CV-B3 and EV-A71 3C proteases 
(Figure 4.41 A and B).  
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Figure 4.41 Results obtained in the cell-based proteolytic assay for the compounds EN2, EN12, D17 
and A4 (A) and for the compounds A4_B, A4_C and A4_D (B). Induction of the Firefly luciferase 
expression was measured in RLU (Relative Light Unit). SG85 (inhibitor of 3C protease) used in the 
concentration 50 μM and CA (Cys147A mutant of CV-B3) served as positive controls.  
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Unfortunately, no inhibition could be detected for any of the compounds. Most probably the 
molecules were not able to enter the cells or were not stable in the applied conditions. Another 
hypothesis could be related to the insufficient solubility of the inhibitors that were unable to 
reach minimal necessary concentration. The sequence similarity between 3C protease from 
CV-B3 (used in the assay) and EV-B93 is 97 %. Only 6 amino acids are different and they are 
not placed in the proteolytic active side, thus suggesting that the lack of inhibitory activity of 
compounds is not caused by the differences in the proteases that were used in the assay.  
 
4.4.10.2 Cytopathic effect (CPE)-based antiviral assay 

In parallel another cell-based method was used in order to check if the compounds are able to 
extend the lifespan of the virus-infected cells. The in vitro cytopathic effect (CPE)-based assay 
is a one-step procedure for evaluating antiviral efficacy of a drug. Virus-susceptible cells (BGM 
cells) were treated with a test compound and then infected with a virus (CV-B3 – genus: 
Enterovirus, species: Enterovirus B or ERAV genus: Apthovirus, species: Equine rhinitis A 
virus). After a 3 day-post-inoculation period, untreated cells exhibited full CPE. Cell viability 
was assessed using MTT assay reagent and results were confirmed by microscopy. In this assay, 
the inhibitors of virus replication were detected by an increase in the viability of the virus 
infected cells. Cells not infected by the virus, but treated with the inhibitors in different 
concentrations served as a toxicity control (Figure 4.42 A and B).  
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Figure 4.42 Results obtained in the CPE-based antiviral assay for EN2, EN12, D17 and A4 (A) and for 
A4_B, A4_C, A4_D (B). Blue data series corresponds to the uninfected cells treated with different 
concentrations of the compounds. Red and orange data series correspond to CV-B3- and ERAV-
infected cells, respectively, treated with different concentrations of the compounds. Asterisk indicates 
the lowest concentration with compound precipitate. Relative cell viability was adjusted to pretreated 
conditions. 
 
Compounds A4, EN2, EN12 and D17 were tested in the cells infected only with CV-B3, 
while the molecules A4_B, A4_C and A4_D were evaluated in the cells infected by both CV-
B3 and ERAV. The results clearly show that none of the compounds exhibited antiviral 
activity. A4, EN2 and EN12 were not cytotoxic at 200 μM (the highest concentration tested), 
while D17 showed cytotoxicity at 2 mM (the highest concentration tested). Furthermore, in 
the case of the analogs of A4, the compound A4_D showed the highest cytotoxicity at 30 μM. 
The molecules A4_B and A4_C exhibited strong cytotoxicity at 1 mM and were the least 
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soluble compounds giving some precipitation at 30 μM. The results are in agreement with the 
ones obtained previously in the cell-based proteolytic assay.  
Lipophilicity expressed as clogP is especially important drug-like property, the control of which 
is important for ultimate success of the drug development. ClogP influences on drug potency, 
pharmacokinetics and toxicity since it governs the cell membrane permeability and affinity to 
usually hydrophobic protein binding sites. If lipophilicity is too high, there is an increased 
likelihood of binding to multiple targets that results in toxicity as well as poor solubility.  
Lack of inhibitory activity and toxicity of the compounds EN2 and D17 may be caused by 
relatively low clogP values equal to 2.35 and 1.40, respectively. Polarity and the presence of 
ionizable carboxylic group influence the cell membrane permeability and make the molecules 
unable to reach their target. On the other hand, the compounds EN12 and A4 seem to be 
sufficiently lipophilic (clogP equal to 2.9 and 4.3, respectively) to enter the cells, however no 
observed inhibitory effect and poor solubility suggest their inability to reach proper inhibitory 
concentration outside and inside the cells. Finally, the compound A4_D showed moderate 
lipophilicity (clogP 3.2) and the strongest toxicity among all tested compounds, which may 
indicate that it was successful in crossing the cell membranes. Unfortunately, the compound 
was not specific enough towards the 3C protease, which resulted in cell toxicity. However, 
further chemical optimization of the molecule A4_D modulating its affinity and selectivity 
may lead to a potent non-covalent inhibitor of the enteroviral 3C proteases. Lack of 
experimental data on the binding mode of A4_D compelled to perform bioinformatics 
simulations that may finally help to infer the requirements for its association to the protein and 
suggest potency-improving modifications. 
 
4.4.11 Bioinformatics simulations of A4_D binding mode 

In parallel to the crystallization trials, bioinformatics calculations were conducted by Daniel 
Álvarez from the laboratory of prof. Xavier Barril to elucidate the binding mode of the active 
compounds, including EN2, EN12, D17, A4 and A4_D. Unfortunately, the docking 
simulations failed, revealing no clear reliable binding pose. For smaller molecules (e.g. EN2), 
multiple conformations were possible, while in the case of A4 or A4_D the calculated positions 
locate the compound partially outside of the active pocket. The biochemical analysis confirmed 
that both parts of A4_D (EN2 and PA4) are essential for the potency of the molecule. EN2 as 
well as PA4 are able to bind independently to EV-B93 3C protease, but with lower affinities 
than the final A4_D compound (see section 4.4.3). The reason why the docking was not 
successful for the best compound A4_D may be the fact that the molecule does not fit to the 
active site of the protein in the conformation present in the crystal structure. The binding 
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simulations were calculated with the use of the previously solved crystal structure of the 
unbound EV-B93 3C protease. The conformation of the enzyme may differ significantly from 
the one indispensable for creating interaction with A4_D, thus making this protein model 
unsuitable for docking purposes. The results described in the literature mentioned the presence 
of a highly flexible surface loop in the homologous enteroviral (EV-A71, PV, HRV, CV-B3) 
3C proteases, important for recognizing the P2-P4 region of the peptide substrates or 
inhibitors [64, 92, 145, 146]. Presumably, some conformational changes should occur in the 
structure of EV-B93 3C protease to make enough room for larger and not flexible A4_D 
molecule. 
For this reason, modeling of the EV-B93 3C protease-A4_D complex was carried out using 
molecular dynamics (MD) simulations. Firstly, the simulations were performed with the 
protein alone in a mixture of pyridine/water to obtain the information on the conformational 
flexibility of the protease active site (Figure 4.43). Pyridine was chosen to force larger 
conformational changes of the protein.  By applying this strategy, it was possible to look for the 
cavity openings induced by a pyridine ring and investigate which regions of the protein are 
interacting more preferably with a pyridine molecule. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.43 The RMSD values of the EV-B93 3C protease backbone (A), and the backbone and side 
chains (B) during 100 ns of MD simulations in the pyridine/water mixture.  
Monitoring the root mean square deviation (RMSD) values of the protein can give insights 
into its structural conformation throughout the simulation, providing an indication of the 
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stability of the protein and weather the simulation has equilibrated. The RMSD values for EV-
B93 3C protease did not fluctuate much, thus showing that the protein is stable compact, and 
not prone to unfolding process. However, in the presence of the pyridine/water mixture, the 
flexible loop formed by the Leu-127, Gly-128, Gly-129 and Thr-130 separating the S2 from 
the S3/S4 sub-pocket slightly opened forcing the changes in the conformation of the Phe-170, 
His-40, Tyr-25, and Lys-42, thereby making the active pocket more accessible for a ligand. 
The aforementioned protein conformation obtained in the first step of the MD simulations 
and the best pose of the compound A4_D from the docking studies were subjected to the 
subsequent MD simulations. The RMSD values were monitored to control changes and 
stability of the binding position of the molecule A4_D during the simulation process (Figure 
4.44). 
 
Figure 4.44 The RMSD values of A4_D in the presence of EV-B93 3C protease during 100 ns of MD 
simulations. 
 
Figure 4.44 shows that not until 90 ns of MD simulations the ligand was able to change 
significantly its position and found stable conformation within the protease active pocket. The 
differences in the ligand binding poses throughout the simulations are represented in the 
Figure 4.45.  
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Figure 4.45 Binding poses of A4_D throughout the MD simulations. Initial (0 ns), intermediate (50 
ns) and final (100 ns) pose is represented as pink, yellow and green sticks, respectively. The residues 
from the catalytic triad are labeled. 
 
The initial binding conformation of A4_D does not differ much from the intermediate pose. 
Only after the final binding mode is completely flipped, it allows the stacking interaction of 
pyridine ring with His-40 and water-mediating interaction with the Glu-71, two conserved 
amino acids from the catalytic triad (Figure 4.46 A). This interaction may explain the 
importance of the nitrogen atom in the ring D, whose absence would render the interactions 
with the Glu-71 impossible. 
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Figure 4.46 EV-B93 3C protease-A4_D interaction diagram (A), and 3D EV-B93 3C protease -A4_D 
interaction model (B). The inhibitor is represented as green sticks. Water molecule is represented as red 
sphere. Amino acid side chains interacting with A4_D are represented as celadon sticks and are labeled. 
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Compound A4_D occupies the S4, S3 and partially the S2 sub-pocket, changing the shape of 
the last considerably. Analyzing the protein-ligand interaction model (which is one of the many 
possible, since the protein and the inhibitor molecule oscillate continuously), it is noticeable 
that the most frequent interactions are hydrophobic (Figure 4.46 B). They are formed by the 
phenyl ring A with the Leu-125, and Phe-170 as well as the sulphur from the ring C with the 
Val-162 and Leu-127.  Compound A4_D is, to a large degree, solvent exposed, therefore, not 
many residues may be subjected to affinity-improving modifications. However, there are some 
possibilities. Firstly, the nitrogen atom in the ring D should be substituted by a hydroxyl 
group, which may interact directly with the Glu-71. Additionally, the nitrogen atom from the 
peptide bond should be replaced by a carbon atom since it is buried in the molecule and is not 
able to form any interaction with the protein. Moreover, its proximity to the carbonyl oxygen 
from the amide bond may be unfavorable in terms of the binding stability of the whole 
molecule.  
Results obtained in the simulations helped to explain the probable inability of the compound 
A4_D to interact with EV-B93 3C protease in a crystalline state. Cysteine and serine proteases 
contain an active cavity composed of several sub-pockets, to which excessively extended 
molecules are not able to bind without its previous rearrangement. The compound A4_D can 
serve as an example of such a molecule since it has a relatively large and rigid structure (Figure 
4.47).  
 
Figure 4.47 Model of the proteolytic active site of EV-B93 3C protease in complex with A4_D. Protein 
surface is colored according to the electrostatic potentials with red and blue indicating negative and 
positive charges, respectively. Inhibitor is represented as turquoise sticks. The sub-pockets of the active 
site are labeled. 
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The experimental data revealed its lack of interaction with the crystallized EV-B93 3C protease 
and suggests that the protein conformation, which is indispensable for the binding of A4_D, is 
not favorable in the crystal structure. In order to improve the potency of A4_D, the precise 
binding site should be determined experimentally. Since all methods used by us failed in 
achieving this goal, we propose to use an additional approach to describe the EV-B93 3C 
protease-A4_D interactions: 15N/1H HSQC (Heteronuclear Single Quantum Coherence). This 
technique is considered one of the best assays for detecting protein-ligand interactions [147]. 
The HSQC is able to provide detailed information on which amino acids from a protein 
interacts with an inhibitor. Because of its time consumption it was not possible to perform this 
assay in the time frame of this thesis. 
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1. An in vitro assay was established to test the proteolytic activity of EV-B93 3C protease. 
2. Crystallization screening of EV-B93 3C protease resulted in needle-like crystals that diffract 
up to 1.57 Å.  The structure revealed that the protein adapts a chymotrypsin-like fold similarly 
to other picornavirus 3C proteases and possesses His-40, Glu-71 and Cys-147 as a catalytic 
triad. 
3. Rupintrivir and compound 1 efficiently inhibited EV-B93 3C protease in the in vitro 
proteolytic assay. 
4. Preparation of the complex of EV-B93 3C protease with rupintrivir and compound 1 and its 
crystallization resulted in rhombohedron-like crystals that diffracted up to 1.50 and 1.32 Å, 
respectively. 
5. NZO, NZN and DB5_60 showed good inhibitory activity against EV-B93 3C protease in 
the in vitro proteolytic assay. 
6. The 1.73 Å-resolution crystal structure of EV-B93 3C protease in complex with NZN 
compound was determined and shows the molecule to be attached in the S1 sub-pocket of the 
proteolytic active site. 
7. The STD NMR-based screening of EV-B93 3C protease resulted in the selection of 51 
molecules that were subsequently validated. Compound 241 displayed the highest affinity and 
the highest inhibitory activity in vitro. 
8. 44 analogs of compound 241 were purchased and tested in the in vitro proteolytic assay. 4 
molecules exhibited strong inhibitory activity against EV-B93 3C protease. 
9. The best molecule A4 was subjected to chemical optimization and resulted in compound 
A4_D with a similar IC50 value, but better efficiency. 
10. Selected inhibitors were taken for further evaluation with the homologous 3C proteases 
from EV-A49, EV-D68, AiV, PSV and ERBV-1. The compounds displayed similar or better 
inhibition towards 3C proteases from AiV, PSV and ERBV-1.  
11. Bioinformatics simulations suggested a binding pose for compound A4_D. These 
calculations indicated that a partial reorganization of the active cavity of EV-B93 3C protease 
is required for ligand binding.  
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